Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a ~~non-accelerated filer.~~smaller reporting company. See ~~definition~~the definitions of “large accelerated filer,” “accelerated ~~filer~~filer” and ~~large accelerated filer”~~“smaller reporting company” in Rule 12b-2 of the Exchange Act ~~(Check one)~~:

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

The number of shares of the registrant’s common stock outstanding as of ~~May 2,~~August 1, 2008 was ~~29,529,663.~~29,368,498.


	Fiscal Quarter Ended						Six Months Ended						Fiscal Quarter Ended						Nine Months Ended
	March 28, 2008			March 30, 2007			March 28, 2008			March 30, 2007			June 27, 2008			June 29, 2007			June 27, 2008			June 29, 2007
Sales
Products	$	214,648		$	199,537		$	418,823		$	388,680		$	206,498		$	195,634		$	625,322		$	584,314
Services		33,517			30,393			66,773			59,188			37,951			31,461			104,723			90,649

Total sales		248,165			229,930			485,596			447,868			244,449			227,095			730,045			674,963

Cost of sales
Products		115,953			108,119			227,110			210,139			116,457			107,644			342,951			317,783
Services		19,336			16,316			38,308			32,535			21,809			17,532			60,733			50,067

Total cost of sales		135,289			124,435			265,418			242,674			138,266			125,176			403,684			367,850

Gross profit		112,876			105,495			220,178			205,194			106,183			101,919			326,361			307,113

Operating expenses
Selling, general and administrative		67,603			65,255			133,583			126,456			68,797			64,366			202,380			190,822
Research and development		18,190			16,103			35,370			31,713			18,519			16,879			53,889			48,592
Purchased in-process research and development														1,488			—			1,488			—

Total operating expenses		85,793			81,358			168,953			158,169			88,804			81,245			257,757			239,414

Operating earnings		27,083			24,137			51,225			47,025			17,379			20,674			68,604			67,699
Impairment of private company equity investment (Note 14)		(3,018	)		—			(3,018	)		—			—			—			(3,018	)		—
Interest income		1,751			1,368			3,688			2,637			1,200			1,622			4,888			4,259
Interest expense		(435	)		(456	)		(884	)		(990	)		(390	)		(454	)		(1,274	)		(1,444	)

Earnings before income taxes		25,381			25,049			51,011			48,672			18,189			21,842			69,200			70,514
Income tax expense		9,594			8,767			17,640			17,035			6,823			7,291			24,463			24,326

Net earnings	$	15,787		$	16,282		$	33,371		$	31,637		$	11,366		$	14,551		$	44,737		$	46,188

Net earnings per share:
Basic	$	0.53		$	0.54		$	1.11		$	1.04		$	0.39		$	0.48		$	1.50		$	1.52

Diluted	$	0.52		$	0.53		$	1.09		$	1.02		$	0.38		$	0.47		$	1.48		$	1.49

Shares used in per share calculations:
Shares used in per share calculation:
Basic		29,830			30,420			30,080			30,504			29,340			30,469			29,833			30,497

Diluted		30,243			30,932			30,598			30,956			29,728			30,983			30,309			31,028

See accompanying Notes to the Unaudited Condensed Consolidated Financial Statements.


	March 28, 2008		September 28, 2007		June 27, 2008		September 28, 2007
ASSETS
Current assets
Cash and cash equivalents	$	157,423	$	196,396	$	128,215	$	196,396
Accounts receivable, net		201,328		187,429		189,192		187,429
Inventories		172,446		140,533		184,790		140,533
Deferred taxes		38,415		38,068		38,175		38,068
Prepaid expense and other current assets		19,158		17,332
Prepaid expenses and other current assets						19,277		17,332

Total current assets		588,770		579,758		559,649		579,758
Property, plant and equipment, net		113,389		110,792		114,975		110,792
Goodwill		208,118		193,760		230,430		193,760
Intangible assets, net		32,445		31,572		42,664		31,572
Other assets		18,756		20,951		20,376		20,951

Total assets	$	961,478	$	936,833	$	968,094	$	936,833

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current liabilities
Current portion of long-term debt	$	6,250	$	6,250	$	—	$	6,250
Accounts payable		79,252		72,588		78,603		72,588
Deferred profit		9,290		13,641		10,531		13,641
Accrued liabilities		168,546		159,109		173,007		159,109

Total current liabilities		263,338		251,588		262,141		251,588
Long-term debt		18,750		18,750		18,750		18,750
Deferred taxes		4,039		4,050		7,302		4,050
Other liabilities		42,835		44,358		44,206		44,358

Total liabilities		328,962		318,746		332,399		318,746

Commitments and contingencies (Notes 5, 6, 8, 9, 10, 11, 12 and 15)

Stockholders’ equity
Preferred stock—par value $0.01, authorized—1,000 shares; issued—none		—		—		—		—
Common stock—par value $0.01, authorized—99,000 shares; issued and outstanding—29,481 shares at March 28, 2008 and 30,345 shares at September 28, 2007		357,214		351,330
Common stock—par value $0.01, authorized—99,000 shares; issued and outstanding—29,350 shares at June 27, 2008 and 30,345 shares at September 28, 2007						360,067		351,330
Retained earnings		179,607		199,471		182,981		199,471
Accumulated other comprehensive income		95,695		67,286		92,647		67,286

Total stockholders’ equity		632,516		618,087		635,695		618,087

Total liabilities and stockholders’ equity	$	961,478	$	936,833	$	968,094	$	936,833

See accompanying Notes to the Unaudited Condensed Consolidated Financial Statements.


	Six Months Ended						Nine Months Ended
	March 28, 2008			March 30, 2007			June 27, 2008			June 29, 2007
Cash flows from operating activities
Net earnings	$	33,371		$	31,637		$	44,737		$	46,188
Adjustments to reconcile net earnings to net cash provided by operating activities:
Depreciation and amortization		13,279			14,072			21,217			21,163
Gain on disposition of property, plant and equipment		(298	)		(207	)		(452	)		(196	)
Impairment of private company equity investment		3,018			—			3,018			—
Purchased in-process research and development								1,488			—
Share-based compensation expense		4,822			5,714			7,207			7,890
Deferred taxes		(1,656	)		(1,146	)		(540	)		(1,802	)
Changes in assets and liabilities, excluding effects of acquisitions:
Accounts receivable, net		(1,732	)		1,330			10,735			2,245
Inventories		(23,718	)		(7,004	)		(31,046	)		(9,703	)
Prepaid expenses and other current assets		(992	)		—			490			(436	)
Other assets		(35	)		(75	)		(726	)		(212	)
Accounts payable		3,287			(3,763	)		1,222			(6,488	)
Deferred profit		(4,474	)		(455	)		(3,966	)		(3,269	)
Accrued liabilities		3,813			(8,001	)		3,200			272
Other liabilities		1,047			2,265			3,041			3,613

Net cash provided by operating activities		29,732			34,367			59,625			59,265

Cash flows from investing activities
Proceeds from sale of property, plant and equipment		787			3,154			1,265			3,193
Purchase of property, plant and equipment		(9,208	)		(5,970	)		(16,674	)		(10,879	)
Purchase of businesses, net of cash acquired		(15,209	)		(4,781	)		(52,898	)		(5,066	)
Private company equity investments		(18	)		—			(18	)		—

Net cash used in investing activities		(23,648	)		(7,597	)		(68,325	)		(12,752	)

Cash flows from financing activities
Repayment of debt		—			(1,250	)		(6,250	)		(2,500	)
Repurchase of common stock		(71,523	)		(51,955	)		(81,892	)		(69,582	)
Issuance of common stock		13,233			20,209			15,761			26,748
Excess tax benefit from share-based plans		2,963			5,747			3,151			7,070
Transfers to Varian Medical Systems, Inc.		(422	)		(348	)		(600	)		(381	)

Net cash used in financing activities		(55,749	)		(27,597	)		(69,830	)		(38,645	)

Effect of exchange rate changes on cash and cash equivalents		10,692			6,974
Effects of exchange rate changes on cash and cash equivalents								10,349			9,317

Net (decrease) increase in cash and cash equivalents		(38,973	)		6,147			(68,181	)		17,185
Cash and cash equivalents at beginning of period		196,396			154,155			196,396			154,155

Cash and cash equivalents at end of period	$	157,423		$	160,302		$	128,215		$	171,340

See accompanying Notes to the Unaudited Condensed Consolidated Financial Statements.

These unaudited interim condensed consolidated financial statements of Varian, Inc. and its subsidiary companies (collectively, the “Company”) have been prepared pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) have been condensed or omitted pursuant to such rules and regulations. The September 28, 2007 balance sheet data was derived from audited financial statements, but does not include all disclosures required in audited financial statements by U.S. GAAP. These unaudited interim condensed consolidated financial statements should be read in conjunction with the financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended September 28, 2007 filed with the SEC. In the opinion of the Company’s management, the unaudited interim condensed consolidated financial statements include all normal recurring adjustments necessary to present fairly the information required to be set forth therein. The results of operations for the ~~six~~nine months ended ~~March 28,~~June 27, 2008 are not necessarily indicative of the results to be expected for a full year or for any other periods.

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.

The Company designs, develops, manufactures, markets, sells and services scientific instruments (including related software, consumable products, accessories and services) and vacuum products ~~(and~~(including related accessories and services). These businesses primarily serve life science, industrial (which includes environmental, food and energy), academic and research customers.

Until April 2, 1999, the business of the Company was operated as the Instruments Business of Varian Associates, Inc. (“VAI”). On that date, VAI distributed to the holders of its common stock one share of common stock of the Company and one share of common stock of Varian Semiconductor Equipment Associates, Inc. (“VSEA”), which was formerly operated as the Semiconductor Equipment business of VAI, for each share of VAI (the “Distribution”). VAI retained its Health Care Systems business and changed its name to Varian Medical Systems, Inc. (“VMS”). Transfers made to VMS under the terms of the Distribution are reflected as financing activities in the Unaudited Condensed Consolidated Statement of Cash Flows.

Fiscal Periods. The Company’s fiscal years reported are the 52- or 53-week periods ending on the Friday nearest September 30. Fiscal year 2008 will comprise the 53-week period ending October 3, 2008, and fiscal year 2007 was comprised of the 52-week period ended September 28, 2007. The fiscal quarters and ~~six~~nine months ended ~~March 28,~~June 27, 2008 and ~~March 30,~~June 29, 2007 each comprised 13 weeks and 2639 weeks, respectively.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

Comprehensive Income. A summary of the components of the Company’s comprehensive income follows:


	Fiscal Quarter Ended				Six Months Ended				Fiscal Quarter Ended					Nine Months Ended
	March 28, 2008		March 30, 2007		March 28, 2008		March 30, 2007		June 27, 2008			June 29, 2007		June 27, 2008		June 29, 2007
(in thousands)
Net earnings	$	15,787	$	16,282	$	33,371	$	31,637	$	11,366		$	14,551	$	44,737	$	46,188
Other comprehensive income:
Other comprehensive (loss) income:
Currency translation adjustment		27,583		4,001		28,407		18,767		(3,048	)		6,673		25,359		25,440

Total other comprehensive income		27,583		4,001		28,407		18,767
Total other comprehensive (loss) income										(3,048	)		6,673		25,359		25,440

Total comprehensive income	$	43,370	$	20,283	$	61,778	$	50,404	$	8,318		$	21,224	$	70,096	$	71,628


	Fiscal Quarter End
	March 28, 2008		September 28, 2007		June 27, 2008		September 28, 2007
(in thousands)
Inventories
Raw materials and parts	$	79,880	$	64,130	$	87,288	$	64,130
Work in process		28,517		24,842		33,153		24,842
Finished goods		64,049		51,561		64,349		51,561

Total	$	172,446	$	140,533	$	184,790	$	140,533

The Company enters into foreign exchange forward contracts to minimize the short-term impact of foreign currency fluctuations on assets and liabilities denominated in non-functional currencies. These contracts are accounted for under Statement of Financial Accounting Standards No. (“SFAS”) 133,Accounting for Derivative Instruments and Hedging Activities. Typically, gains and losses on these contracts are substantially offset by transaction losses and gains on the underlying balances being hedged. During the fiscal quarter and ~~six~~nine months ended ~~March 28,~~June 27, 2008, net foreign currency gains relating to these arrangements were ~~$0.6~~$0.7 million and ~~$0.9~~$1.5 million, respectively. During the fiscal quarter and ~~six~~nine months ended ~~March 30,~~June 29, 2007, net foreign currency losses relating to these arrangements were ~~$0.5~~$0.4 million and ~~$0.8~~$1.2 million, respectively. These amounts were recorded in selling, general and administrative expenses.

From time to time, the Company also enters into foreign exchange forward contracts to minimize the impact of foreign currency fluctuations on forecasted transactions. These contracts are designated as cash flow hedges under SFAS 133. At ~~March 28,~~June 27, 2008, there were no outstanding foreign exchange forward contracts designated as cash flow hedges of forecasted transactions. During the fiscal quarters and ~~six~~nine months ended ~~March 28,~~June 27, 2008 and ~~March 30,~~June 29, 2007, no foreign exchange gains or losses from hedge ineffectiveness were recognized.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

The Company’s foreign exchange forward contracts generally range from one to 12 months in original maturity. A summary of all foreign exchange forward contracts that were outstanding as of ~~March 28,~~June 27, 2008 follows:


	Notional Value Sold		Notional Value Purchased		Notional Value Sold		Notional Value Purchased
(in thousands)
Australian dollar					$	—	$	43,281
Euro	$	—	$	30,788		—		28,715
Australian dollar		—		44,803
British pound		—		9,716		—		11,971
Swiss franc						—		4,510
Canadian dollar						3,255		—
Japanese yen		5,586		—		3,248		—
Canadian dollar		3,569		—
Swedish krona						2,337		—
Polish zloty						—		1,634

Total	$	9,155	$	85,307	$	8,840	$	90,111

Analogix Business.On November 11, 2007, the Company acquired certain assets and assumed certain liabilities of Analogix, Inc. (the “Analogix Business”) for approximately $11 million in cash and assumed net debt, subject to certain net asset adjustments. Under the terms of the acquisition, the Company might make additional purchase price payments of up to $4 million over a three-year period, depending on the performance of the Analogix Business and certain operational milestones. The Analogix Business designs, manufactures, markets, sells and services consumables and instrumentation for automated compound purification using flash chromatography, and became part of the Scientific Instruments segment.

Oxford Diffraction Ltd. On April 4, 2008, the Company acquired Oxford Diffraction Ltd. (“Oxford Diffraction”) for approximately $39 million in cash and assumed net debt, subject to certain net asset adjustments. Under the terms of the acquisition, the Company might make additional purchase price payments of up to $10 million over a three-year period, depending on the future financial performance of the Oxford Diffraction business. Oxford Diffraction designs, manufactures, markets, sells and services instruments and consumables for x-ray crystallography, an analytical technique used by scientists in pharmaceutical research and other research laboratories to determine the structure of both small molecules and large molecules such as proteins. Oxford Diffraction became part of the Scientific Instruments segment.

In connection with the Oxford Diffraction acquisition, the Company has completed a preliminary valuation of identified intangible assets (including purchased in-process research and development) which was used to prepare the initial purchase price allocation for accounting purposes. This valuation is expected to be finalized in the fourth quarter of fiscal year 2008 and may result in adjustments to the final purchase price allocation.

Based on the results of the preliminary valuation, the Company recorded a one-time charge of $1.5 million during the third quarter of fiscal year 2008 to immediately expense acquired in-process research and development related to projects that were in process but incomplete at the time of the acquisition.

Contingent Consideration Arrangements. The Company is, from time to time, obligated to pay additional cash purchase price amounts in the event that certain financial or operational milestones are met by acquired

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

businesses. As of ~~March 28,~~June 27, 2008, up to a maximum of ~~$33.3~~$43.9 million could be payable through ~~December 2010~~April 2011 under contingent consideration arrangements relating to acquired businesses. Amounts subject to these arrangements can be earned over the respective measurement period, depending on the performance of the acquired business relative to certain financial and/or operational targets.

The following table summarizes ~~key terms of outstanding~~ contingent consideration arrangements as of ~~March 28,~~June 27, 2008:

~~NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)~~

Changes in the carrying amount of goodwill for each of the Company’s reporting segments in the first ~~six~~nine months of fiscal year 2008 were as follow:


	Scientific Instruments		Vacuum Technologies		Total Company		Scientific Instruments		Vacuum Technologies		Total Company
(in thousands)
Balance as of September 28, 2007	$	192,794	$	966	$	193,760	$	192,794	$	966	$	193,760
Fiscal year 2008 acquisitions		5,772		—		5,772		29,247		—		29,247
Contingent payments on prior-year acquisitions		4,057		—		4,057		4,057		—		4,057
Foreign currency impacts and other adjustments		4,529		—		4,529		3,366		—		3,366

Balance as of March 28, 2008	$	207,152	$	966	$	208,118
Balance as of June 27, 2008							$	229,464	$	966	$	230,430

As required by SFAS 142,Goodwill and Other Intangible Assets, the Company performs an annual goodwill impairment assessment. This assessment is performed in the second quarter of each fiscal year. During the second quarter of fiscal ~~quarter ended March 28,~~year 2008, the Company completed its annual impairment test and determined that there was no impairment of goodwill.

The following intangible assets have been recorded and are being amortized by the Company:


	September 28, 2007							June 27, 2008
	Gross		Accumulated Amortization			Net		Gross		Accumulated Amortization			Net
(in thousands)
Intangible assets
Existing technology	$	16,611	$	(8,235	)	$	8,376	$	17,790	$	(9,841	)	$	7,949
Patents and core technology		29,908		(10,752	)		19,156		45,816		(14,117	)		31,699
Trade names and trademarks		2,458		(1,623	)		835		2,451		(1,884	)		567
Customer lists		11,866		(9,408	)		2,458		12,288		(10,399	)		1,889
Other		3,025		(2,278	)		747		3,144		(2,584	)		560

Total	$	63,868	$	(32,296	)	$	31,572	$	81,489	$	(38,825	)	$	42,664

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

Amortization expense relating to intangible assets was ~~$2.0~~$2.4 million and ~~$3.8~~$6.2 million during the fiscal quarter and ~~six~~nine months ended ~~March 28,~~June 27, 2008, respectively. Amortization expense relating to intangible assets was ~~$2.0~~$1.8 million and ~~$4.3~~$6.1 million during the fiscal quarter and ~~six~~nine months ended ~~March 30,~~June 29, 2007, respectively. At ~~March 28,~~June 27, 2008, estimated amortization expense for the remainder of fiscal year 2008 and for each of the five succeeding fiscal years and thereafter follows:


	Estimated Amortization Expense		Estimated Amortization Expense
(in thousands)
Six months ending October 3, 2008	$	3,905
Fiscal quarter ending October 3, 2008			$	2,414
Fiscal year 2009		6,804		8,652
Fiscal year 2010		6,299		8,148
Fiscal year 2011		3,814		5,680
Fiscal year 2012		2,974		4,836
Fiscal year 2013		2,662		4,431
Thereafter		5,987		8,503

Total	$	32,445	$	42,664

Summary of Restructuring Plans.Between fiscal years 2003 and 2007, the Company committed to several restructuring plans in order to adjust its organizational structure, improve operational efficiencies and eliminate redundant or excess costs resulting from acquisitions or dispositions during those periods.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

The following table sets forth changes in the Company’s aggregate liability relating to all restructuring plans (including the Fiscal Year 2007 Plan described below) during the first, second and ~~second~~third quarters of fiscal year 2008 as well as total restructuring expense and other related costs recorded since the inception of those plans:


		Employee- Related			Facilities- Related			Total			Employee- Related			Facilities- Related			Total
(in thousands)
Balance at September 28, 2007		$	2,222		$	707		$	2,929		$	2,222		$	707		$	2,929
Charges to expense, net			453			761			1,214			453			761			1,214
Cash payments			(181	)		(131	)		(312	)		(181	)		(131	)		(312	)
Foreign currency impacts and other adjustments			24			(24	)		—			24			(24	)		—

Balance at December 28, 2007			2,518			1,313			3,831			2,518			1,313			3,831
Charges to expense, net			51			—			51			51			—			51
Cash payments			(1,020	)		(65	)		(1,085	)		(1,020	)		(65	)		(1,085	)
Foreign currency impacts and other adjustments			36			138			174			36			138			174

Balance at March 28, 2008		$	1,585		$	1,386		$	2,971			1,585			1,386			2,971
Charges to expense, net												294			—			294
Cash payments												(107	)		(88	)		(195	)
Foreign currency impacts and other adjustments												(4	)		(21	)		(25	)

Balance at June 27, 2008											$	1,768		$	1,277		$	3,045


Total expense since inception of plans
(in millions)
Restructuring expense	Restructuring expense							$	18.9								$	19.2

Other restructuring-related costs⁽¹⁾	Other restructuring-related costs⁽¹⁾							$	6.7								$	8.1

~~NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)~~

Fiscal Year 2007 Plan. During the third quarter of fiscal year 2007, the Company committed to a plan to combine and optimize the development and assembly of most of its NMR and mass spectrometry products, to further centralize related administration and other functions and to reallocate certain resources toward more rapidly growing product lines and geographies. As part of the plan, the Company is creating an information rich detection (“IRD”) center in Walnut Creek, California, where NMR operations currently located in Palo Alto, California ~~will be~~are being integrated with mass spectrometry operations already located in Walnut Creek. The Company ~~will invest~~is investing in a new 45,000 square foot building and a substantial remodel of an existing building there to house the IRD center.

As a result of the plan, a number of employee positions have been or will be relocated or eliminated and certain facilities have been or will be consolidated. These actions primarily impact the Scientific Instruments segment and involve the elimination of between approximately 40 and 60 positions. The Company expects these activities to be completed during ~~the first half of~~ fiscal year 2009.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

Restructuring and other related costs associated with this plan include one-time termination benefits, retention payments, costs to relocate facilities (including decommissioning costs, moving costs and temporary facility/storage costs), accelerated depreciation of fixed assets to be disposed as a result of facilities actions and lease termination costs.

The following table sets forth changes in the Company’s restructuring liability relating to the foregoing plan during the first, second and ~~second~~third quarters of fiscal year 2008:


		Employee- Related			Facilities- Related			Total				Employee- Related			Facilities- Related			Total
(in thousands)
Balance at September 28, 2007		$	2,222		$	—		$	2,222			$	2,222		$	—		$	2,222
Charges to expense, net			453			761			1,214				453			761			1,214
Cash payments			(181	)		(77	)		(258	)			(181	)		(77	)		(258	)
Foreign currency impacts and other adjustments			24			(20	)		4				24			(20	)		4

Balance at December 28, 2007			2,518			664			3,182				2,518			664			3,182
Charges to expense, net			51			—			51				51			—			51
Cash payments			(1,020	)		(44	)		(1,064	)			(1,020	)		(44	)		(1,064	)
Foreign currency impacts and other adjustments			36			136			172				36			136			172

Balance at March 28, 2008		$	1,585		$	756		$	2,341				1,585			756			2,341
Charges to expense, net													294			—			294
Cash payments													(107	)		(64	)		(171	)
Foreign currency impacts and other adjustments													(4	)		(11	)		(15	)

Balance at June 27, 2008												$	1,768		$	681		$	2,449


Total expense since inception of plan
Total expense since inception of plans
(in millions)
Restructuring expense	Restructuring expense							$	3.6		Restructuring expense							$	3.9

Other restructuring-related costs	Other restructuring-related costs							$	3.3		Other restructuring-related costs							$	4.7

The restructuring charges of ~~$0.1~~$0.3 million and ~~$1.3~~$1.6 million recorded during the fiscal quarter and ~~six~~nine months ended ~~March 28,~~June 27, 2008 related to employee termination benefits and costs associated with the closure of leased facilities. The Company also incurred ~~$0.5~~$1.4 million and ~~$1.3~~$2.7 million in other restructuring-related costs during the fiscal quarter and ~~six~~nine months ended ~~March 28,~~June 27, 2008, respectively. These costs were related to employee retention costs and facilities-related costs including decommissioning costs and non-cash charges for accelerated depreciation of assets to be disposed upon the closure of facilities.

~~NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)~~

Product Warranties. The Company’s products are generally subject to warranties. Liabilities for the estimated future costs of repair or replacement are established and charged to cost of sales at the time the related sale is recognized. The amount of liability to be recorded is based on management’s best estimates of future warranty costs after considering historical and projected product failure rates and product repair costs.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

Changes in the Company’s estimated liability for product warranty during the ~~six~~nine months ended ~~March 28,~~June 27, 2008 and ~~March 30,~~June 29, 2007 follow:


	Six Months Ended						Nine Months Ended
	March 28, 2008			March 30, 2007			June 27, 2008			June 29, 2007
(in thousands)
Beginning balance	$	12,454		$	11,042		$	12,454		$	11,042
Charges to costs and expenses		1,972			2,743			3,571			3,856
Warranty expenditures and other adjustments		(1,451	)		(2,040	)		(3,521	)		(3,433	)
Acquired warranty liabilities								1,098			—

Ending balance	$	12,975		$	11,745		$	13,602		$	11,465

Indemnification Obligations. Financial Accounting Standards Board (“FASB”) Interpretation No. (“FIN”) 45,Guarantor’s Accounting and Disclosure Requirements for Guarantees, Including Indirect Guarantees of Indebtedness of Others, requires a guarantor to recognize a liability for and/or disclose obligations it has undertaken in relation to the issuance of the guarantee. Under this guidance, arrangements involving indemnification clauses are subject to the disclosure requirements of FIN 45 only.

The Company is subject to certain indemnification obligations to VMS (formerly VAI) and VSEA in connection with the Instruments business as conducted by VAI prior to the Distribution (described in Note 2). These indemnification obligations cover a variety of aspects of the Company’s business, including, but not limited to, employee, tax, intellectual property, litigation and environmental matters. Certain of the agreements containing these indemnification obligations are disclosed as exhibits to the Company’s Annual Report on Form 10-K. The estimated fair value of these indemnification obligations is not considered to be material.

The Company is subject to certain indemnification obligations to Jabil in connection with the Company’s sale of its Electronics Manufacturing Business to Jabil. These indemnification obligations cover certain aspects of the Company’s conduct of the Electronics Manufacturing Business prior to its sale to Jabil, including, but not limited to, tax and environmental matters. The agreement containing these indemnification obligations is disclosed as an exhibit to the Company’s Annual Report on Form 10-K. The estimated fair value of these indemnification obligations is not considered to be material.

The Company’s By-Laws require it to indemnify its officers and directors, as well as those who act as directors and officers of other entities at the request of the Company, against expenses, judgments, fines, settlements and other amounts actually and reasonably incurred in connection with any proceedings arising out of their services to the Company. In addition, the Company has entered into separate indemnity agreements with each director and officer that provide for indemnification of these directors and officers under certain circumstances. The form of these indemnity agreements is disclosed as an exhibit to the Company’s Annual Report on Form 10-K. The indemnification obligations are more fully described in these indemnity agreements and the Company’s By-Laws. The Company purchases insurance to cover claims or a portion of any claims made against its directors and officers. Since a maximum obligation is not explicitly stated in the Company’s By-Laws

~~NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)~~

or these indemnity agreements and will depend on the facts and circumstances that arise out of any future claims, the overall maximum amount of the obligations cannot reasonably be estimated. Historically, the Company has not made payments related to these indemnification obligations and the estimated fair value of these indemnification obligations is not considered to be material.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

As is customary in the Company’s industry and as provided for in local law in the U.S. and other jurisdictions, many of the Company’s standard contracts provide remedies to customers and other third parties with whom the Company enters into contracts, such as defense, settlement or payment of judgment for intellectual property claims related to the use of its products. From time to time, the Company also agrees to indemnify customers, suppliers, contractors, lessors, lessees and others with whom it enters into contracts, against loss, expense and/or liability arising from various triggering events related to the sale and the use of the Company’s products and services, the use of their goods and services, the use of facilities and other matters covered by such contracts, usually up to a specified maximum amount. In addition, from time to time, the Company sometimes also agrees to indemnify these parties against claims related to undiscovered liabilities, additional product liability or environmental obligations. Claims made under such indemnification obligations have been insignificant and the estimated fair value of these indemnification obligations is not considered to be material.

Credit Facilities. The Company maintains relationships with banks in many countries from whom it sometimes obtains bank guarantees and short-term standby letters of credit. These guarantees and letters of credit relate primarily to advance payments and deposits made to the Company’s subsidiaries by customers for which separate liabilities are recorded in the unaudited condensed consolidated financial statements. As of ~~March 28,~~June 27, 2008, a total of ~~$21.6~~$23.2 million of these bank guarantees and letters of credit were outstanding. No amounts had been drawn by beneficiaries under these or any other outstanding guarantees or letters of credit as of that date.

Long-term Debt. As of ~~both March 28,~~June 27, 2008, ~~and September 28, 2007,~~ the Company had ~~a $25.0~~an $18.8 million term loan outstanding with a U.S. financial ~~institution~~institution. The balance outstanding under this term loan was $25.0 million at aSeptember 28, 2007. As of both June 27, 2008 and September 28, 2007, the fixed interest rate ofon the term loan was 6.7%. The term loan contains certain covenants that limit future borrowings and the payment of cash dividends and require the maintenance of certain levels of working capital and operating results. The Company was in compliance with all restrictive covenants of the term loan agreement at ~~March 28,~~June 27, 2008.

The following table summarizes future principal payments on borrowings under long-term debt outstanding as of ~~March 28,~~June 27, 2008:


	Six Months Ending Oct. 3, 2008		Fiscal Years												Total		Fiscal Quarter Ending Oct. 3, 2008		Fiscal Years												Total
			2009		2010		2011		2012		2013		Thereafter						2009		2010		2011		2012		2013		Thereafter
(in thousands)
Long-term debt (including current portion)	$	6,250	$	—	$	6,250	$	—	$	6,250	$	—	$	6,250	$	25,000	$	—	$	—	$	6,250	$	—	$	6,250	$	—	$	6,250	$	18,750

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

Net Periodic Pension Cost. The components of net periodic pension cost relating to the Company’s defined benefit retirement plans follow:


	Fiscal Quarter Ended						Six Months Ended						Fiscal Quarter Ended						Nine Months Ended
	March 28, 2008			March 30, 2007			March 28, 2008			March 30, 2007			June 27, 2008			June 29, 2007			June 27, 2008			June 29, 2007
(in thousands)
Service cost	$	343		$	334		$	686		$	668		$	343		$	334		$	1,029		$	1,002
Interest cost		723			626			1,446			1,252			723			626			2,169			1,878
Expected return on plan assets		(653	)		(512	)		(1,306	)		(1,024	)		(653	)		(512	)		(1,959	)		(1,536	)
Amortization of prior service cost and actuarial gains and losses		—			111			—			222			—			111			—			333

Net periodic pension cost	$	413		$	559		$	826		$	1,118		$	413		$	559		$	1,239		$	1,677

Employer Contributions. During the fiscal quarter and ~~six~~nine months ended ~~March 28,~~June 27, 2008, the Company made contributions totaling $0.3 million and ~~$0.7~~$1.0 million to its defined benefit pension plans. The Company currently anticipates contributing an additional ~~$0.7~~$0.4 million to these plans in the ~~remaining six months~~fourth quarter of fiscal year 2008.

Environmental Matters. The Company’s operations are subject to various federal, state and local laws in the U.S. as well as laws in other countries regulating the discharge of materials into the environment or otherwise relating to the protection of the environment. These regulations increase the costs and potential liabilities of the Company’s operations. However, the Company does not currently anticipate that its compliance with these regulations will have a material effect on the Company’s capital expenditures, earnings or competitive position.

The Company and VSEA are each obligated (under the terms of the Distribution described in Note 2) to indemnify VMS for one-third of certain costs (after adjusting for any insurance recoveries and tax benefits recognized or realized by VMS for such costs) relating to (a) environmental investigation, monitoring and/or remediation activities at certain facilities previously operated by VAI and third-party claims made in connection with environmental conditions at those facilities, and (b) U.S. Environmental Protection Agency or third-party claims alleging that VAI or VMS is a potentially responsible party under the Comprehensive Environmental Response Compensation and Liability Act of 1980, as amended (“CERCLA”) in connection with certain sites to which VAI allegedly shipped manufacturing waste for recycling, treatment or disposal (the “CERCLA sites”). With respect to the facilities formerly operated by VAI, VMS is overseeing the environmental investigation, monitoring and/or remediation activities, in most cases under the direction of or in consultation with federal, state and/or local agencies, and handling third-party claims. VMS is also handling claims relating to the CERCLA sites. The Company is also undertaking environmental investigation and/or monitoring activities at one of its facilities under the direction of or in consultation with governmental agencies.

Various uncertainties make it difficult to estimate future costs for certain of these environmental-related activities, specifically external legal expenses, VMS’ internal oversight costs, third-party claims and a former VAI facility where the likelihood and scope of further environmental-related activities are difficult to assess. As of ~~March 28,~~June 27, 2008, it was nonetheless estimated that the Company’s future exposure for these environmental-related costs ranged in the aggregate from ~~$1.2~~$1.1 million to $2.6 million. The time frame over which these costs are expected to be incurred varies with each type of cost, ranging up to approximately 22 years as of June 27, 2008.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

~~expected to be incurred varies with each type of cost, ranging up to approximately 22 years as of March 28, 2008.~~ No amount in the foregoing range of estimated future costs is discounted, and no amount in the range is believed to be more probable of being incurred than any other amount in such range. The Company therefore had an accrual of ~~$1.2~~$1.1 million as of ~~March 28,~~June 27, 2008 for these future environmental-related costs.

Sufficient knowledge has been gained to be able to better estimate other costs for future environmental-related activities. As of ~~March 28,~~June 27, 2008, it was estimated that the Company’s future costs for these environmental-related activities ranged in the aggregate from $2.9 million to $12.8 million. The time frame over which these costs are expected to be incurred varies, ranging up to approximately 22 years as of ~~March 28,~~June 27, 2008. As to each of these ranges of cost estimates, it was determined that a particular amount within the range was a better estimate than any other amount within the range. Together, these amounts totaled $5.8 million at ~~March 28,~~June 27, 2008. Because both the amount and timing of the recurring portion of these costs were reliably determinable, that portion is discounted at 4%, net of inflation. The Company therefore had an accrual of ~~$4.0~~$4.1 million as of ~~March 28,~~June 27, 2008, which represents its best estimate of these future environmental-related costs after discounting estimated recurring future costs. This accrual is in addition to the ~~$1.2~~$1.1 million described in the preceding paragraph.

The Company has not reduced any environmental-related liability in anticipation of recoveries from third parties. However, an insurance company has agreed to pay a portion of certain of VAI’s (now VMS’) future environmental-related costs, for which the Company has an indemnification obligation, and the Company therefore has a long-term receivable of $1.0 million (discounted at 4%, net of inflation) in other assets as of ~~March 28,~~June 27, 2008, for the Company’s share of that insurance recovery.

The Company believes that its reserves for the foregoing and other environmental-related matters are adequate, but as the scope of its obligation becomes more clearly defined, these reserves may be modified and related charges against or credits to earnings may be made. Although any ultimate liability arising from environmental-related matters could result in significant expenditures that, if aggregated and assumed to occur within a single fiscal year, would be material to the Company’s financial statements, the likelihood of such occurrence is considered remote. Based on information currently available and its best assessment of the ultimate amount and timing of environmental-related events, the Company believes that the costs of environmental-related matters are not reasonably likely to have a material adverse effect on the Company’s financial condition or results of operations.

Legal Proceedings. The Company is involved in pending legal proceedings that are ordinary, routine and incidental to its business. While the ultimate outcome of these legal matters is not determinable, the Company believes that these matters are not reasonably likely to have a material adverse effect on the Company’s financial condition or results of operations.

Share-Based Compensation Expense. The Company accounts for share-based awards in accordance with the provisions of SFAS 123(R),Share-Based Payment.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

The following table summarizes the amount of share-based compensation expense by award type as well as the effect of this expense on net earnings and net earnings per share:


	Fiscal Quarter Ended						Six Months Ended						Fiscal Quarter Ended						Nine Months Ended
	March 28, 2008			March 30, 2007			March 28, 2008			March 30, 2007			June 27, 2008			June 29, 2007			June 27, 2008			June 29, 2007
(in thousands, except per share amounts)
Share-based compensation expense by award type:
Employee and non-employee director stock options	$	(1,823	)	$	(1,902	)	$	(2,791	)	$	(3,980	)	$	(1,359	)	$	(1,424	)	$	(4,150	)	$	(5,404	)
Employee stock purchase plan		(253	)		(308	)		(563	)		(503	)		(224	)		(219	)		(787	)		(722	)
Restricted (nonvested) stock⁽¹⁾		(802	)		(534	)		(1,243	)		(1,106	)		(802	)		(533	)		(2,045	)		(1,639	)
Non-employee director stock units		(225	)		(125	)		(225	)		(125	)		—			—			(225	)		(125	)

Total share-based compensation expense (effect on earnings before income taxes)		(3,103	)		(2,869	)		(4,822	)		(5,714	)		(2,385	)		(2,176	)		(7,207	)		(7,890	)
Effect on income tax expense		762			1,062			1,326			2,085			744			794			2,070			2,879

Effect on net earnings	$	(2,341	)	$	(1,807	)	$	(3,496	)	$	(3,629	)	$	(1,641	)	$	(1,382	)	$	(5,137	)	$	(5,011	)


Effect on net earnings per share:
Basic	$	(0.08	)	$	(0.06	)	$	(0.12	)	$	(0.12	)	$	(0.06	)	$	(0.05	)	$	(0.17	)	$	(0.16	)

Diluted	$	(0.07	)	$	(0.06	)	$	(0.11	)	$	(0.12	)	$	(0.06	)	$	(0.04	)	$	(0.17	)	$	(0.16	)

Share-based compensation expense has been included in the Company’s unaudited condensed consolidated statement of earnings as follows:


	Fiscal Quarter Ended				Six Months Ended				Fiscal Quarter Ended				Nine Months Ended
	March 28, 2008		March 30, 2007		March 28, 2008		March 30, 2007		June 27, 2008		June 29, 2007		June 27, 2008		June 29, 2007
(in thousands)
Cost of sales	$	108	$	111	$	232	$	219	$	106	$	103	$	338	$	322
Selling, general and administrative		2,878		2,632		4,339		5,241		2,164		1,936		6,503		7,177
Research and development		117		126		251		254		115		137		366		391

Total	$	3,103	$	2,869	$	4,822	$	5,714	$	2,385	$	2,176	$	7,207	$	7,890

Stock Options.Under the Omnibus Stock Plan (“OSP”), the Company periodically grants stock options to officers, directors and employees. The exercise price for stock options granted under the OSP may not be less than 100% of the fair market value at the date of the grant. Options granted are exercisable at the times and on the terms established by the Compensation Committee, but not later than ten years after the date of grant (except in the event of death, after which an option is exercisable for three years). Options granted generally become exercisable in cumulative installments of one-third each year commencing one year following the date of grant.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

The following table summarizes stock option activity under the OSP for the ~~six~~nine months ended ~~March 28,~~June 27, 2008:


	Shares		Weighted- Average Exercise Price		Aggregate Grant Date Fair Value ⁽¹⁾		Shares		Weighted Average Exercise Price		Aggregate Grant Date Fair Value ⁽¹⁾
	(in thousands)				(in millions)		(in thousands)				(in millions)
Outstanding at September 28, 2007	1,783		$	38.43			1,783		$	38.43
Granted	276		$	68.38	$	5.4	288		$	67.53	$	5.5
Exercised	(317	)	$	35.14			(360	)	$	35.26
Cancelled or expired	(2	)	$	41.72			(7	)	$	56.97

Outstanding at March 28, 2008	1,740		$	43.77
Outstanding at June 27, 2008							1,704		$	43.95

As of ~~March 28,~~June 27, 2008, ~~the unrecorded deferred~~unrecognized share-based compensation ~~balance~~expense related to stock options was ~~$7.1~~$5.8 million. This amount will be recognized as expense using the straight-line attribution method over ~~an estimated~~a weighted-average amortization period of ~~1.3~~1.2 years.

Restricted (Nonvested) Stock.Under the OSP, the Company also periodically grants restricted (nonvested) common stock to employees. Such grants are valued using the quoted market value of the underlying common stock as of the grant date. ~~These amounts are~~The fair value of these shares is then recognized by the Company as share-based compensation expense ratably over their respective vesting periods, which range from one to three years.

The following table summarizes restricted (nonvested) common stock activity under the OSP for the ~~six~~nine months ended ~~March 28,~~June 27, 2008:


	Shares		Weighted- Average Grant Date Fair Value		Aggregate Grant Date Fair Value		Shares		Weighted Average Grant Date Fair Value		Aggregate Grant Date Fair Value
	(in thousands)				(in millions)		(in thousands)				(in millions)
Outstanding and unvested at September 28, 2007	111		$	43.92			111		$	43.92
Granted	42		$	69.44	$	2.9	42		$	69.44	$	2.9
Vested(1)	(41	)	$	39.62			(50	)	$	37.48

Outstanding and unvested at March 28, 2008	112		$	55.07
Outstanding and unvested at June 27, 2008							103		$	57.45

As of ~~March 28,~~June 27, 2008, there was a total of ~~$3.5~~$2.7 million in unrecognized share-based compensation expense related to restricted stock granted under the OSP. This expense ~~is expected to~~will be recognized over a weighted-average amortization period of ~~1.5~~1.3 years.

Non-Employee Director Stock Units. Under the terms of the OSP, on the first business day following each annual meeting of the Company’s stockholders, each person then serving as a non-employee director is automatically granted stock units having an initial value of $45,000 (beginning in fiscal year 2008) and $25,000 (prior to fiscal year 2008). The stock units will vest upon termination of the director’s service on the Board of Directors and will then be satisfied by issuance of shares of the Company’s common stock. Each non-employee director who holds stock units will not have rights as a stockholder with respect to the shares issuable thereunder

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

until such shares are paid out. The stock units are not transferable, except to the non-employee director’s designated beneficiary or estate in the event of his or her death. During the ~~fiscal quarters~~nine months ended ~~March 28,~~June 27, 2008

~~NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)~~

and ~~March 30,~~June 29, 2007, the Company granted stock units with an aggregate value of $225,000 and $125,000, respectively, to non-employee members of its Board of Directors (of which there were five) and recognized the total value as share-based compensation expense at the time of grant.

Employee Stock Purchase Plan.During the fiscal quarter and ~~six~~nine months ended ~~March 28,~~June 27, 2008, employees purchased approximately ~~21,000~~20,000 shares for ~~$1.2~~$1.0 million and ~~41,000~~61,000 shares for ~~$2.1~~$3.1 million, ~~respectively.~~respectively, under the Company’s Employee Stock Purchase Plan (“ESPP”). During the fiscal quarter and ~~six~~nine months ended ~~March 30,~~June 29, 2007, employees purchased approximately ~~29,000~~25,000 shares for ~~$1.1~~$0.9 million and ~~55,000~~79,000 shares for ~~$2.0~~$2.9 million, respectively. As of ~~March 28,~~June 27, 2008, a total of approximately ~~226,000~~207,000 shares remained available for issuance under the ESPP.

Stock Repurchase Programs. In February 2008, the Company’s Board of Directors approved a new stock repurchase program under which the Company ~~was~~is authorized to utilize up to $100 million to repurchase shares of its common stock. This repurchase program is effective through December 31, 2009. During the ~~fiscal quarter~~nine months ended ~~March 28,~~June 27, 2008, the Company repurchased and retired ~~376,000~~567,000 shares under this authorization at an aggregate cost of ~~$20.2~~$30.5 million. As of ~~March 28,~~June 27, 2008, the Company had remaining authorization to repurchase ~~$79.8~~$69.5 million of its common stock under this program.

In January 2007, the Company’s Board of Directors approved a stock repurchase program under which the Company was authorized to utilize up to $100 million to repurchase shares of its common stock. This repurchase program is effective through December 31, 2008. During the ~~six~~nine months ended ~~March 28,~~June 27, 2008, the Company repurchased and retired 876,000 shares under this authorization at an aggregate cost of $50.4 million, which completed this repurchase program.

Other Stock Repurchases.During the ~~six~~nine months ended ~~March 28,~~June 27, 2008, the Company repurchased and retired ~~12,000~~14,000 shares tendered to it by employees in settlement of employee tax withholding obligations due from those employees upon the vesting of restricted stock.

The Company has equity investments in privately held companies which, because of its ownership interest and other factors, are carried at cost. The Company monitors these investments for impairment.

During the second quarter of fiscal year 2008, the Company became aware of information which raised substantial doubt about the ability of a small, privately held company in which the Company holds a cost-method equity investment to continue as a going concern. Based on this information, the Company determined that the fair value of its investment had declined and that the decline was other-than-temporary. As a result, the Company wrote off the entire $3.0 million carrying value of its investment via an impairment charge in the period.

Effective September 29, 2007, the Company adopted FIN 48,Accounting for Uncertainty in Income ~~Taxes—~~Taxes – An Interpretation of FASB Statement No 109, which addresses accounting for, and disclosure of, uncertain tax positions. FIN 48 prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. As a result of the adoption of FIN 48, the Company reduced its liability for unrecognized tax benefits and increased deferred tax

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

assets by $2.4 million and $0.6 million, respectively. These adjustments were aggregated and accounted for as a cumulative effect of a change in accounting principle, which resulted in an increase to retained earnings of $3.0 million. The total amount of unrecognized tax benefits excluding interest thereon as of the date of adoption was $6.9 million, substantially all of which would impact the effective tax rate if realized. The Company’s policy to

~~NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)~~

include interest and penalties related to income taxes within income tax expense did not change as a result of implementing FIN 48. As of the date of adoption of FIN 48, the Company had accrued $0.7 million in income taxes payable for the payment of interest and penalties related to unrecognized tax benefits.

The Company’s U.S. federal, state and local income tax returns and non-U.S. income tax returns are subject to audit by relevant tax authorities. The Company’s income tax reporting periods beginning after fiscal year ~~2003~~2004 for the U.S. and after fiscal year 2001 for the Company’s major non-U.S. jurisdictions remain generally open to audit by relevant tax authorities.

During the fiscal quarter ended March 28, 2008, total unrecognized tax benefits were increased by $0.2 million due to additions for current-year unrecognized tax benefits. This increase resulted in a corresponding tax expense in the fiscal quarter ended March 28, 2008. During the six months ended March 28,June 27, 2008, total unrecognized tax benefits were decreased by ~~$0.9~~$0.6 million due to the lapse of certain statutes of limitations in the ~~first quarter,~~period which resulted in a ~~$1.3~~$1.0 million reduction, which was partially offset by additions for current-year unrecognized tax benefits. During the nine months ended June 27, 2008, total unrecognized tax benefits were decreased by $1.5 million due to the lapse of certain statutes of limitations in the period which resulted in a $2.3 million reduction, partially offset by additions for current-year unrecognized tax benefits. ~~This~~These net ~~decrease~~decreases resulted in a corresponding tax ~~benefit~~benefits in the ~~six~~fiscal quarter and nine months ended ~~March 28, 2008.~~June 27, 2008, respectively.

At ~~March 28,~~June 27, 2008, the total amount of unrecognized tax benefits was ~~$6.0~~$5.4 million, substantially all of which would impact the effective tax rate if realized. Income taxes payable at ~~March 28,~~June 27, 2008 included accrued interest and penalties of ~~$0.7~~$0.5 million. Although the timing and outcome of income tax audits is highly uncertain, it is possible that certain unrecognized tax benefits could decrease in the next twelve months due to the lapse of certain statutes of limitation and result in a reduction in the annual effective tax rate of up to 1%. Any such reduction could be impacted by other changes in other unrecognized tax benefits.

Basic earnings per share are calculated based on net earnings and the weighted-average number of shares of common stock outstanding during the reported period. Diluted earnings per share are calculated similarly, except that the weighted-average number of common shares outstanding during the period are increased by the number of additional shares of common stock that would have been outstanding if dilutive potential shares of common stock had been issued. The dilutive effect of potential common stock (including outstanding stock options, unvested restricted stock ~~ESPP shares~~ and non-employee director stock units) is reflected in diluted earnings per share by application of the treasury stock method, which includes consideration of share-based compensation as required by SFAS 123(R).

For the fiscal quarter and ~~six~~nine months ended ~~March 28,~~June 27, 2008, options to purchase ~~265,000~~282,000 and 256,000 shares, respectively, were excluded from the calculation of diluted earnings per share as their effect was anti-dilutive. For the fiscal quarter and ~~six~~nine months ended ~~March 30,~~June 29, 2007, options to purchase ~~26,000~~5,000 and ~~30,000~~31,000 shares, respectively, were excluded from the calculation of diluted earnings per share as their effect was anti-dilutive.

~~A reconciliation of weighted-average basic shares outstanding to weighted-average diluted shares outstanding follows:~~

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

A reconciliation of weighted-average basic shares outstanding to weighted-average diluted shares outstanding follows:

For financial reporting purposes, the Company’s operations are grouped into two business segments: Scientific Instruments and Vacuum Technologies. The Scientific Instruments segment designs, develops, manufactures, markets, sells and services equipment and related software, consumable products, accessories and services for a broad range of life science and industrial (which includes environmental, food and energy) applications requiring identification, quantification and analysis of the composition or structure of liquids, solids or gases. The Vacuum Technologies segment designs, develops, manufactures, markets, sells and services vacuum products and related accessories and services used to create, contain, control, measure and test vacuum environments in a broad range of life science and industrial applications requiring ultra-clean or high-vacuum environments. These segments were determined in accordance with SFAS 131,Disclosures about Segments of an Enterprise and Related ~~Information~~Information..

General corporate costs include shared costs of legal, tax, accounting, treasury, insurance and other management costs. A portion of the indirect and common costs has been allocated to the segments through the use of estimates. Also, transactions between segments are accounted for at cost and are not included in sales. Accordingly, the following information is provided for purposes of achieving an understanding of operations, but might not be indicative of the financial results of the reported segments were they independent organizations. In addition, comparisons of the Company’s operations to similar operations of other companies might not be meaningful.

On April 4, 2008, the Company acquired Oxford Diffraction Ltd. (“Oxford Diffraction”) for approximately $37 million in cash and assumed net debt, subject to certain net asset adjustments. Under the terms of the acquisition, the Company might make additional purchase price payments of up to $10 million over a three-year

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

period, depending on the future financial performance of the Oxford Diffraction business. Oxford Diffraction designs, manufactures, markets, sells and services instruments and consumables for x-ray crystallography, an analytical technique used by scientists in pharmaceutical research and other research laboratories to determine the structure of both small molecules and large molecules such as proteins. Oxford Diffraction became part of the Scientific Instruments segment.

In September 2006, the FASB issued SFAS 157, Fair Value Measurements. SFAS 157 defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles and expands disclosures about fair value measurements. SFAS 157 applies to previous accounting pronouncements that require or permit fair value measurements. SFAS 157 is effective for fiscal years beginning after November 15, 2007, with certain exceptions which are described below. In February 2008, the FASB issued FASB Staff Position (“FSP”) 157-1, Application of FASB Statement No. 157 to FASB Statement No. 13 and Other Accounting Pronouncements That Address Fair Value Measurements for Purposes of Lease Classification or Measurement under Statement 13 (“FSP 157-1”), which amends SFAS 157 to exclude certain leasing ~~transactions~~transaction from its scope. Also in February 2008, the FASB issued FSP 157-2,Effective Date of FASB Statement No. 157,which delays the effective date of SFAS 157 for all nonfinancial assets and nonfinancial liabilities to fiscal years beginning after November 15, 2008, except for items that are recognized or disclosed at fair value in the financial statements on a recurring basis (at least annually). The Company does not expect the adoption of SFAS 157 to have a material impact on its financial condition or results of operations.

In February 2007, the FASB issued SFAS 159,The Fair Value Option for Financial Assets and Financial Liabilities—Including an amendment of FASB Statement 115, which provides companies with an option to measure eligible financial assets and liabilities in their entirety at fair value. The fair value option may be applied instrument by instrument, and may be applied only to entire instruments. If a company elects the fair value option for an eligible item, changes in the item’s fair value must be reported as unrealized gains and losses in earnings at each subsequent reporting date. SFAS 159 is effective for fiscal years beginning after November 15, 2007. The Company is evaluating the options provided under SFAS 159 and their potential impact on its financial condition and results of operations if implemented.

In December 2007, the FASB issued SFAS 141 (revised 2007),Business Combinations, (“SFAS 141(R)”). SFAS 141(R) retains the fundamental requirements of the original pronouncement requiring that the purchase method be used for all business combinations but also provides revised guidance for recognizing and measuring identifiable assets and goodwill acquired, liabilities assumed, and any noncontrolling interest in the acquiree. It also requires the recognition of assets acquired and liabilities assumed arising from contingencies, the capitalization of in-process research and development at fair value, and the expensing of acquisition-related costs as incurred.SFAS 141(R) is effective for fiscal years beginning after December 15, 2008. The Company is currently evaluating the requirements of SFAS 141(R) and does not expect its adoption in the first quarter of

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

fiscal year 2010 to have a material impact on the Company’s financial condition or results of operations. However, in the event that the Company completes acquisitions subsequent to its adoption of SFAS 141(R), the application of its provisions will likely have a material impact on the Company’s results of operations, although the Company is not currently able to estimate that impact.

~~NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)~~

disclosures are required to clearly identify and distinguish between the interests of the parent and the interests of the noncontrolling owners. SFAS 160 is effective for fiscal years beginning after December 15, 2008, and requires retroactive adoption of the presentation and disclosure requirements for existing minority interests. All other requirements are applied prospectively. The Company does not expect the adoption of SFAS 160 to have a material impact on its financial condition or results of operations.

In March 2008, the FASB issued SFAS 161,Disclosures about Derivative Instruments and Hedging Activities, an amendment of FASB Statement No. 133,which requires additional disclosures about the objectives and strategies of the derivative instruments and hedging activities, the method of accounting for such instruments under SFAS 133 and its related interpretations, and a tabular disclosure of the effects of such instruments and related hedged items on the Company’s financial condition and results of operations. SFAS 161 is effective for fiscal years beginning after November 15, 2008. The Company does not expect the adoption of SFAS 161 to have a material impact on its financial condition or results of operations.

In April 2008, the FASB issued FSP 142-3,Determination of the Useful Life of Intangible Assets, which amends the factors that should be considered in developing renewal or extension assumptions used to determine the useful life of a recognized intangible asset. The intent of FSP 142-3 is to improve the consistency between the useful life of a recognized intangible asset under SFAS 142,Goodwill and Other Intangible Assets, and the period of expected cash flows used to measure the fair value of the asset under SFAS 141(R),Business Combinations, and other accounting literature. FSP 142-3 is effective for fiscal years beginning after December 15, 2008, and must be applied prospectively to intangible assets acquired after the effective date. Early adoption is prohibited. Given that FSP 142-3 applies to intangible assets acquired after the effective date, the Company is not yet able to determine whether its adoption will have a material impact on its financial condition or results of operations.

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

Throughout this Report, and particularly in thisItem 2—Management’s Discussion and Analysis of Financial Condition and Results of Operations, there are forward-looking statements that are based upon our current expectations, estimates and projections and that reflect our beliefs and assumptions based upon information available to us at the date of this Report. In some cases, you can identify these statements by words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” ~~“potential,”~~“potential” or “continue,” and other similar terms. These forward-looking statements include (but are not limited to) those relating to the timing and amount of anticipated restructuring ~~costs~~ and other related ~~cost savings,~~costs as well as ~~our expected effective annual tax rate and~~ anticipated capital expenditures in fiscal year 2008.

We caution investors that forward-looking statements are only our current expectations about future events. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and assumptions that are difficult to predict. Our actual results, performance or achievements could differ materially from those expressed or implied by the forward-looking statements. Some of the important factors that could cause our results to differ are discussed inItem 1A—Risk Factors in our Annual Report on Form 10-K for the fiscal year ended September 28, 2007. We encourage you to read that section carefully.

Other risks and uncertainties that could cause actual results to differ materially from those in our forward-looking statements include, but are not limited to, the following: whether we will succeed in new product development, release, commercialization, performance and acceptance; whether we can achieve continued growth in sales for industrial ~~and~~and/or life science applications; whether we can achieve continued sales growth in Europe and Asia Pacific and/or stronger growth in sales in the U.S.; risks arising from the timing of shipments, installations and the recognition of revenues on certain magnet-based products, including nuclear magnetic resonance (“NMR”) spectroscopy systems, magnetic resonance (“MR”) imaging systems and fourier transform mass spectrometry (“FTMS”) systems and superconducting magnets; the impact of shifting product mix on profit margins; competitive products and pricing; economic conditions in our product and geographic markets; whether we will see continued and timely delivery of key raw materials and components by suppliers; foreign currency fluctuations that could adversely impact revenue growth and earnings; whether we will see continued investment in capital equipment, in particular given global liquidity and credit concerns; whether we will see reduced demand from customers that operate in cyclical industries; the impact of any delay or reduction in government funding for research; our ability to successfully evaluate, negotiate and integrate acquisitions; the actual costs, timing and benefits of restructuring activities (such as our Northern California facilities consolidation) and other efficiency improvement activities (such as our global procurement, lower-cost manufacturing and outsourcing initiatives); variability in our effective income tax rate (due to factors including the timing and amount of discrete tax events and changes to unrecognized tax benefits); and other risks detailed from time to time in our filings with the U.S. Securities and Exchange Commission (the “SEC”). We ~~disclaim any intent or~~undertake no special obligation to update ~~publicly~~ any forward-looking statements, whether in response to new information, future events or otherwise.

~~Second~~Third Quarter of Fiscal Year 2008 Compared to ~~Second~~Third Quarter of Fiscal Year 2007

For financial reporting purposes, our operations are grouped into two reportable business segments: Scientific Instruments and Vacuum Technologies. The following table presents comparisons of our sales and operating earnings for each of those segments and in total for the ~~second~~third quarters of fiscal years 2008 and 2007:


	Fiscal Quarter Ended														Fiscal Quarter Ended
	March 28, 2008					March 30, 2007					Increase (Decrease)				June 27, 2008					June 29, 2007					Increase (Decrease)
	$			% of Sales		$			% of Sales		$		%		$			% of Sales		$			% of Sales		$			%
(dollars in millions)
Sales by Segment:
Scientific Instruments	$	204.4		82.4	%	$	190.3		82.8	%	$	14.1	7.4	%	$	200.7		82.1	%	$	187.0		82.3	%	$	13.7		7.3	%
Vacuum Technologies		43.8		17.6			39.6		17.2			4.2	10.5			43.7		17.9			40.1		17.7			3.6		9.0

Total company	$	248.2		100.0	%	$	229.9		100.0	%	$	18.3	7.9	%	$	244.4		100.0	%	$	227.1		100.0	%	$	17.3		7.6	%


Operating Earnings by Segment:
Scientific Instruments	$	22.5		11.0	%	$	21.8		11.4	%	$	0.7	3.3	%	$	12.2		6.1	%	$	17.4		9.3	%	$	(5.2	)	(29.9	)%
Vacuum Technologies		8.8		20.1			7.6		19.3			1.2	15.0			7.8		17.7			7.8		19.5			—		—

Total segments		31.3		12.6			29.4		12.8			1.9	6.3			20.0		8.2			25.2		11.1			(5.2	)	(20.9	)
General corporate		(4.2	)	(1.7	)		(5.3	)	(2.3	)		1.1	(20.6	)		(2.6	)	(1.1	)		(4.5	)	(2.0	)		1.9		43.6

Total company	$	27.1		10.9	%	$	24.1		10.5	%	$	3.0	12.2	%	$	17.4		7.1	%	$	20.7		9.1	%	$	(3.3	)	(15.9	)%

Scientific Instruments. The increase in Scientific Instruments sales was primarily attributable to higher sales volume ~~across a broad range~~ of our ~~products, including~~ analytical instruments and consumable ~~products.~~products, partially offset by lower sales of magnet-based products (primarily due to delayed deliveries and installations of a few large systems). The weaker U.S. dollar and recent acquisitions also had a positive impact on Scientific Instruments sales growth. Sales increased for both industrial (which includes environmental, food and energy) and life science applications.

Scientific Instruments ~~operating earnings~~revenues for the ~~second~~third quarter of fiscal year 2007 do not include sales from acquisitions completed since the third quarter of fiscal year 2007, primarily Oxford Diffraction Limited (“Oxford Diffraction”), which was acquired in April 2008, ~~included acquisition-related intangible amortization of $1.9 million, amortization of $0.1 million related to inventory written up in connection with~~and the ~~acquisition of certain assets and liabilities~~business of Analogix, Inc. (the “Analogix Business”), which was acquired in November 2007. In the aggregate, these acquisitions contributed approximately 1% to Scientific Instruments sales growth in the third quarter of fiscal year 2008 compared to the third quarter of fiscal year 2007.

Scientific Instruments operating earnings for the third quarter of fiscal year 2008 included an acquisition-related in-process research and development charge of $1.5 million, acquisition-related intangible amortization of $2.4 million, amortization of $0.6 million related to inventory written up to fair value in connection with the acquisition of Oxford Diffraction, restructuring and other related costs of ~~$0.5~~$1.7 million and share-based compensation expense of $0.9 million. In comparison, Scientific Instruments operating earnings for the ~~second~~third quarter of fiscal year 2007 included acquisition-related intangible amortization of ~~$2.0~~$1.8 million, ~~amortization of $0.2 million related to inventory written up in connection with the acquisition of IonSpec Corporation (“IonSpec”),~~ restructuring and other related costs of ~~$0.1~~$2.9 million and share-based compensation expense of ~~$0.8~~$0.7 million. Excluding the impact of these items, the decrease in operating earnings as a percentage of sales was ~~primarily~~ attributable to higher transition costs related to the ~~timing~~relocation of ~~costs relating~~manufacturing activities for certain products, the continued weakening of the U.S. dollar (which was favorable to ~~new product introductions~~reported sales but unfavorable to reported operating margins) and, ~~cost reduction and efficiency initiatives, which were partially offset by~~to a lesser extent, the ~~positive impact~~transition effect of ~~favorable sales mix, sales volume leverage and cost reduction activities favorably impacting selling, general and administrative expenses.~~acquisitions completed in the quarter.

We expect our initiatives to relocate manufacturing activities for certain products to have some residual negative impact on revenue and profitability in the fourth quarter of fiscal 2008.

Vacuum Technologies. The increase in Vacuum Technologies sales was driven by higher sales volume ~~particularly~~across a broad range of ~~turbomolecular pumps.~~the segment’s products and services. The weaker U.S. dollar also had a positive impact on Vacuum Technologies sales growth. Sales ~~into~~increased for both industrial ~~applications increased strongly while sales into~~and life science ~~applications increased modestly.~~applications.

Vacuum Technologies operating earnings for the ~~second~~third quarters of fiscal years 2008 and 2007 include the impact of share-based compensation expense of $0.2 million and $0.1 million, respectively. Excluding the impact of these items, the ~~increase~~decrease in Vacuum Technologies operating earnings as a percentage of sales is primarily ~~due to~~the result of the continued weakening of the U.S. dollar, which was only partially offset by the positive impact of sales volume leverage ~~(as~~in the ~~higher sales volume improved the absorption rate~~third quarter of ~~fixed and semi-variable costs).~~

The following table presents comparisons of our sales and other selected consolidated financial results for the ~~second~~third quarters of fiscal years 2008 and 2007:


	Fiscal Quarter Ended															Fiscal Quarter Ended
	March 28, 2008					March 30, 2007					Increase (Decrease)					June 27, 2008					June 29, 2007					Increase (Decrease)
	$			% of Sales		$			% of Sales		$			%		$			% of Sales		$			% of Sales		$			%
(dollars in millions, except per share data)
Sales	$	248.2		100.0	%	$	229.9		100.0	%	$	18.3		7.9	%	$	244.4		100.0	%	$	227.1		100.0	%	$	17.3		7.6	%

Gross profit		112.9		45.5			105.5		45.9			7.4		7.0			106.2		43.4			101.9		44.9			4.3		4.2


Operating expenses:
Selling, general and administrative		67.6		27.3			65.3		28.4			2.3		3.6			68.8		28.1			64.3		28.4	%		4.5		6.9
Research and development		18.2		7.3			16.1		7.0			2.1		13.6			18.5		7.6			16.9		7.4			1.6		9.7
Purchased in-process research and development																	1.5		0.6			—		—			1.5		100.0

Total operating expenses		85.8		34.6			81.4		35.4			4.4		5.5			88.8		36.3			81.2		35.8			7.6		9.3


Operating earnings		27.1		10.9			24.1		10.5			3.0		12.2			17.4		7.1			20.7		9.1			(3.3	)	(15.9	)
Impairment of private company equity investment		(3.0	)	(1.2	)		—		—			(3.0	)	100.0
Interest income		1.7		0.7			1.4		0.6			0.3		28.0			1.2		0.5			1.6		0.7			(0.4	)	(26.0	)
Interest expense		(0.4	)	(0.2	)		(0.5	)	(0.2	)		0.1		(4.6	)		(0.4	)	(0.2	)		(0.4	)	(0.2	)		—		14.0
Income tax expense		(9.6	)	(3.8	)		(8.7	)	(3.8	)		(0.9	)	9.4			(6.8	)	(2.8	)		(7.3	)	(3.2	)		0.5		6.4

Net Earnings	$	15.8		6.4	%	$	16.3		7.1	%	$	(0.5	)	(3.0	)%
Net earnings																$	11.4		4.6	%	$	14.6		6.4	%	$	(3.2	)	(21.9	)%

Net earnings per diluted share	$	0.52				$	0.53				$	(0.01	)			$	0.38				$	0.47				$	(0.09	)

Sales. As discussed under the headingSegment Results above, sales by ~~the~~our Scientific Instruments and Vacuum Technologies segments in the ~~second~~third quarter of fiscal year 2008 increased by ~~7.4%~~7.3% and ~~10.5%~~9.0%, respectively, compared to the prior-year quarter. ~~On a~~The growth in consolidated ~~basis,~~ sales ~~grew 7.9% in the second quarter of fiscal year 2008. This growth~~ was broad-based, with increases in sales of products for both industrial (which includes environmental, food and energy) and life science applications. ~~The~~Recent acquisitions and the weaker U.S. dollar also had a positive effect on the reported sales ~~increases.~~increases, while delayed deliveries and installations of a few large magnet-based products had a negative effect. Sales from acquisitions completed since the third quarter of fiscal year 2007 contributed approximately 1% to consolidated sales growth in the third quarter of fiscal year 2008 compared to the third quarter of fiscal year 2007.

For geographic reporting purposes, we use four regions—North America (excluding Mexico), Europe (including the Middle East and Africa), Asia Pacific (including India) and Latin America (including Mexico). Sales by geographic region in the ~~second~~third quarters of fiscal years 2008 and 2007 were as follow:


	Fiscal Quarter Ended												Fiscal Quarter Ended
	March 28, 2008				March 30, 2007				Increase (Decrease)				June 27, 2008				June 29, 2007				Increase (Decrease)
	$		% of Sales		$		% of Sales		$		%		$		% of Sales		$		% of Sales		$		%
(dollars in millions)
Sales by Geographic Region:
Geographic Region
North America	$	72.7	29.3	%	$	71.3	31.0	%	$	1.4	2.0	%	$	79.2	32.4	%	$	79.0	34.8	%	$	0.2	0.2	%
Europe		105.0	42.3			94.6	41.2			10.4	11.0			98.1	40.1			90.4	39.8			7.7	8.5
Asia Pacific		53.8	21.7			50.1	21.8			3.7	7.2			51.5	21.1			47.4	20.9			4.1	8.8
Latin America		16.7	6.7			13.9	6.0			2.8	20.5			15.6	6.4			10.3	4.5			5.3	52.0

Total company	$	248.2	100.0	%	$	229.9	100.0	%	$	18.3	7.9	%	$	244.4	100.0	%	$	227.1	100.0	%	$	17.3	7.6	%

~~The sales increase~~Sales in North America ~~was primarily driven~~were essentially flat, with higher Vacuum Technologies sales offset by slightly lower Scientific Instruments sales. The sales increases in Europe and Asia Pacific were attributable to higher sales ~~of analytical instruments, which were partially offset~~ by lower sales of low-volume, high-selling price magnet-based products and, to a lesser extent, vacuum products. The increase in sales in Europe was attributable to stronger demand for a broad range of products in both ~~our~~the Scientific Instruments and Vacuum Technologies segments. The ~~increase in sales in Asia Pacific was primarily attributable to stronger demand for our analytical instruments and vacuum products. The~~ sales increase in Latin America was ~~primarily~~ attributable to ~~stronger demand for our analytical instruments.~~higher Scientific Instruments sales.

~~As described above, the~~The sales increase in ~~North America~~Europe was less pronounced compared to the prior-year quarter due to the timing of sales of certain low-volume, high-selling price magnet-based products. We do not consider this ~~geographic shift~~ to be indicative of any particular trend for magnet-based products as a whole, but rather to be reflective of the variability in results that these low-volume, high-selling price magnet-based products can create.

Gross Profit. Gross profit for the ~~second~~third quarter of fiscal year 2008 reflects the impact of ~~$1.5~~$2.0 million in amortization expense relating to acquisition-related intangible assets, ~~$0.1~~$0.6 million in amortization expense related to inventory written up to fair value primarily in connection with the acquisition of ~~the Analogix Business, $0.2~~Oxford Diffraction, $0.5 million in restructuring and other related costs and share-based compensation expense of $0.1 million. In comparison, gross profit for the ~~second~~third quarter of fiscal year 2007 reflects the impact of $1.3 million in amortization expense relating to acquisition-related intangible assets, ~~$0.2~~$0.7 million in ~~amortization expense~~restructuring and other related ~~to inventory written up in connection with the IonSpec acquisition~~costs and share-based compensation expense of $0.1 million. Excluding the impact of these items, the decrease in gross profit as a percentage of sales ~~decreased slightly,~~was primarily ~~as a~~the result of higher transition costs related to the relocation of manufacturing activities for certain products, the weaker U.S. dollar (which ~~increased~~was favorable to reported ~~revenues~~sales but ~~lowered~~unfavorable to reported gross profit margins). and, to a lesser extent, higher freight costs.

Selling, General and Administrative. Selling, general and administrative expenses for the ~~second~~third quarter of fiscal year 2008 included $0.4 million in amortization expense relating to acquisition-related intangible assets, ~~$0.2~~$0.9 million in restructuring and other related costs and ~~$2.8~~$2.1 million in share-based compensation expense. In comparison, selling, general and administrative expenses for the ~~second~~third quarter of fiscal year 2007 included ~~$0.7~~$0.5 million in amortization expense relating to acquisition-related intangible assets, ~~$0.1~~$1.9 million in restructuring and other related costs and ~~$2.6~~$1.9 million in share-based compensation expense. Excluding the impact of these items, the ~~decrease~~slight increase in selling, general and administrative expenses as a percentage of sales was primarily due to the ~~result of sales volume leverage and cost reduction activities. The benefit from these positive factors was partially offset by~~weaker U.S. dollar, higher costs relating to new product introductions and ~~cost reduction and efficiency initiatives~~the transition effect of acquisitions completed during the ~~second~~quarter, partially offset by lower employee bonus accruals in the third quarter of fiscal year 2008.

Research and Development. Research and development expenses for the ~~second~~third quarter of fiscal year 2008 reflect the impact of restructuring and other related costs of ~~$0.2~~$0.3 million and $0.1 million in share-based compensation expense. In comparison, research and development expenses for the ~~second~~third quarter of fiscal year

2007 reflect the impact of restructuring and other related costs of $0.3 million and share-based compensation expense of $0.1 million. Excluding the impact of these items, the slight increase in research and development expenses ~~increased~~ as a percentage of sales was primarily due to higher costs relating to new product ~~introductions.~~introductions and product transition activities.

Purchased In-Process Research and Development.In connection with the Oxford Diffraction acquisition in the third quarter of fiscal year 2008, we recorded a one-time charge of $1.5 million to immediately expense acquired in-process research and development related to projects that were in process but incomplete at the time of the acquisition.

Restructuring Activities. Between fiscal years 2003 and 2007, we committed to several restructuring plans in order to adjust our organizational structure, improve operational efficiencies and eliminate redundant or excess costs resulting from acquisitions or dispositions during those periods.From the respective inception dates of these plans through ~~March 28,~~June 27, 2008, we have incurred a total of ~~$18.9~~$19.2 million in restructuring expense and a total of ~~$6.7~~$8.1 million in other costs related directly to those plans (comprised primarily of employee retention and relocation costs and accelerated depreciation of assets disposed upon the closure of facilities). During the ~~second~~third quarter of fiscal year 2008, there was no significant activity under these plans except for the fiscal year 2007 plan as described below.

centralize related administration and other functions and to reallocate certain resources toward more rapidly growing product lines and geographies. As part of the plan, we are creating an information rich detection (“IRD”) center in Walnut Creek, California, where NMR operations currently located in Palo Alto, California ~~will be~~are being integrated with mass spectrometry operations already located in Walnut Creek. Merging our IRD talent base into this single location will capitalize on our strength in NMR and mass spectrometry and enhance our ability to develop innovative IRD solutions that are more powerful, complementary, routine and user-friendly. Underscoring our commitment to IRD and the benefits that a combined location and organization will provide, we are investing in a new 45,000 square foot building and a substantial remodel of an existing building there to house the IRD center.

As a result of the plan, a number of employee positions have been or will be relocated or eliminated and certain facilities have been or will be consolidated. These actions primarily impact the Scientific Instruments segment and involve the elimination of between approximately 40 and 60 positions. We expect these activities to be completed during ~~the first half of~~ fiscal year 2009.

Restructuring and other related costs associated with this plan include one-time employee termination benefits, employee retention payments, costs to relocate facilities (including decommissioning costs, moving costs and temporary facility/storage costs), accelerated depreciation of fixed assets to be disposed as a result of facilities actions and lease termination costs.

The following table sets forth changes in our restructuring liability relating to the foregoing plan during the ~~second~~third quarter of fiscal year 2008 as well as total restructuring expense and other restructuring-related costs recorded since the inception of the plan:


		Employee- Related			Facilities- Related			Total				Employee- Related			Facilities- Related			Total
(in thousands)
Balance at December 28, 2007		$	2,518		$	664		$	3,182
Balance at March 28, 2008												$	1,585		$	756		$	2,341
Charges to expense, net			51			—			51				294			—			294
Cash payments			(1,020	)		(44	)		(1,064	)			(107	)		(64	)		(171	)
Foreign currency impacts and other adjustments			36			136			172				(4	)		(11	)		(15	)

Balance at March 28, 2008		$	1,585		$	756		$	2,341
Balance at June 27, 2008												$	1,768		$	681		$	2,449


Total expense since inception of plan
Total expense since inception of plans
(in millions)
Restructuring expense	Restructuring expense							$	3.6		Restructuring expense							$	3.9

Other restructuring related costs								$	3.3
Other restructuring-related costs											Other restructuring-related costs							$	4.7

The restructuring charges of ~~$0.1~~$0.3 million recorded during the ~~second~~third quarter of fiscal year 2008 related to employee termination benefits. We also incurred ~~$0.5~~$1.4 million in other restructuring-related costs during the quarter, which were comprised of ~~$0.4~~$0.7 million in employee retention costs and ~~$0.1~~$0.7 million in facilities-related costs including decommissioning costs and a non-cash charge for accelerated depreciation of assets to be disposed upon the closure of facilities.

~~Impairment of Private Company Equity Investment.~~ During the second quarter of fiscal year 2008, we became aware of information which raised substantial doubt about the ability of a small, private company in which we hold a cost-method equity investment to continue as a going concern. Based on this information, we determined that the fair value of our investment had declined and that the decline was other-than-temporary. As a result, we wrote off the entire $3.0 million carrying value of our investment via an impairment charge in the period.

Income Tax Expense.The effective income tax rate was ~~37.8%~~37.5% for the ~~second~~third quarter of fiscal year 2008, compared to ~~35.0%~~33.4% for the ~~second~~third quarter of fiscal year 2007. The higher effective income tax rate ~~for~~in the ~~second~~third quarter of fiscal year 2008 was primarily due to higher ~~than~~U.S. taxes on foreign earnings, a non-deductible in-process research and development charge related to the ~~rate for~~acquisition of Oxford Diffraction in April 2008 and higher non-deductible compensation expense. These factors were partially offset by the ~~second~~benefit from a larger reduction in unrecognized tax benefits due to the lapse of certain statutes of limitations in the third quarter of fiscal year ~~2007 due primarily to certain taxes on intercompany dividends and the expiration of the U.S. federal research and development tax credit in December 2007.~~2008.

Net Earnings. Net earnings for the ~~second~~third quarter of fiscal year 2008 reflect an acquisition-related in-process research and development charge of $1.5 million and the after-tax impacts of ~~a $3.0 million impairment of a private company equity investment, $1.9~~$2.4 million in acquisition-related intangible amortization, ~~$0.1~~$0.6 million in amortization related to inventory written up to fair value in connection with the acquisition of ~~the Analogix Business, $0.5~~Oxford Diffraction, $1.7 million in restructuring and other related costs and ~~$3.0~~$2.3 million in share-based compensation expense. Net earnings for the ~~second~~third quarter of fiscal year 2007 reflect the after-tax impacts of ~~$2.0~~$1.8 million in acquisition-related intangible amortization, ~~$0.2 million in amortization related to inventory written up in connection with the acquisition of IonSpec, $0.1~~$2.9 million in restructuring and other related costs and ~~$2.9~~$2.1 million in share-based compensation expense. Excluding the after-tax impact of these items, the ~~increase~~decrease in net earnings in the ~~second~~third quarter of fiscal year 2008 ~~resulted~~was primarily ~~from~~attributable to higher ~~sales volume (including sales volume leverage on operating expenses), which was partially offset by a~~transition costs related to the relocation of manufacturing activities for certain products and higher ~~effective income tax rate.~~costs relating to new product introductions.

~~Subsequent Event~~~~. On April 4, 2008, we acquired Oxford Diffraction Ltd. (“Oxford Diffraction”)~~We expect our initiatives to relocate manufacturing activities for ~~approximately $37 million~~certain products to have some residual negative impact on revenue and profitability in ~~cash and assumed net debt, subject to certain net asset adjustments. Under~~ the ~~terms~~fourth quarter of the acquisition, we might make additional purchase price payments of up to $10 million over a three-year period, depending on the future financial performance of the Oxford Diffraction business. Oxford Diffraction designs, manufactures, markets, sells and services instruments and consumables for x-ray crystallography, an analytical technique used by scientists in pharmaceutical research and other research laboratories to determine the structure of both small molecules and large molecules such as proteins. Following its acquisition, Oxford Diffraction became part of the Scientific Instruments segment.fiscal 2008.

First ~~Six~~Nine Months of Fiscal Year 2008 Compared to First ~~Six~~Nine Months of Fiscal Year 2007

The following table presents comparisons of our sales and operating earnings for each of our Scientific Instruments and Vacuum Technologies segments and in total for the first ~~six~~nine months of fiscal years 2008 and 2007:


	Six Months Ended										Increase (Decrease)				Nine Months Ended
	March 28, 2008					March 30, 2007					Increase (Decrease)				June 27, 2008					June 29, 2007					Increase (Decrease)
	$			% of Sales		$			% of Sales		$		%		$			% of Sales		$			% of Sales		$			%
(dollars in millions)
Sales by Segment:
Scientific Instruments	$	401.4		82.7	%	$	367.2		82.0	%	$	34.2	9.3	%	$	602.1		82.5	%	$	554.2		82.1	%	$	47.9		8.7	%
Vacuum Technologies		84.2		17.3			80.7		18.0			3.5	4.4			127.9		17.5			120.8		17.9			7.1		5.9

Total company	$	485.6		100.0	%	$	447.9		100.0	%	$	37.7	8.4	%	$	730.0		100.0	%	$	675.0		100.0	%	$	55.0		8.2	%

Operating Earnings by Segment:
Scientific Instruments	$	42.3		10.5	%	$	40.7		11.1	%	$	1.6	4.1	%	$	54.5		9.1	%	$	58.0		10.5	%	$	(3.5	)	(6.1	)%
Vacuum Technologies		16.5		19.6			16.0		19.9			0.5	3.1			24.3		19.0			23.9		19.7			0.4		1.7

Total segments		58.8		12.1			56.7		12.7			2.1	3.8			78.8		10.8			81.9		12.1			(3.1	)	(3.8	)
General corporate		(7.6	)	(1.6	)		(9.7	)	(2.2	)		2.1	(21.3	)		(10.2	)	(1.4	)		(14.2	)	(2.1	)		4.0		28.5

Total company	$	51.2		10.5	%	$	47.0		10.5	%	$	4.2	8.9	%	$	68.6		9.4	%	$	67.7		10.0	%	$	0.9		1.3	%

Scientific Instruments. The increase in Scientific Instruments sales was primarily attributable to higher sales volume ~~in particular from~~across a broad range of our analytical ~~instruments.~~instruments and consumable products, partially offset by lower sales of magnet-based products. The weaker U.S. dollar and recent acquisitions also had a positive impact on Scientific Instruments sales growth. Sales increased for both industrial (which includes environmental, food and energy) and life science applications.

Scientific Instruments revenues for the first nine months of fiscal year 2007 do not include sales from acquisitions completed subsequent to that period, primarily Oxford Diffraction and the Analogix Business. Excluding sales from these acquisitions, Scientific Instruments sales in the first nine months of fiscal year 2008 increased by approximately 8% compared to the first nine months of fiscal year 2007.

Scientific Instruments operating earnings for the first ~~six~~nine months of fiscal year 2008 included an acquisition-related in-process research and development charge of $1.5 million, acquisition-related intangible amortization of ~~$3.7~~$6.1 million, amortization of ~~$0.6~~$1.2 million related to inventory written up ~~primarily~~to fair value in connection with the acquisitions of ~~IonSpec and~~Oxford Diffraction, the Analogix Business and IonSpec Corporation (“IonSpec”), restructuring and other related costs of ~~$2.5~~$4.2 million and share-based compensation expense of ~~$1.7~~$2.6 million. In comparison, Scientific Instruments operating earnings for the first ~~six~~nine months of fiscal year 2007 included acquisition-related intangible amortization of ~~$4.2~~$6.0 million, amortization of $0.5 million related to inventory written up to fair value in connection with the acquisition of IonSpec, restructuring and other related costs of ~~$0.2~~$3.1 million and share-based compensation expense of ~~$1.9~~$2.6 million. Excluding the impact of these items, operating earnings were ~~slightly~~ lower as a percentage of ~~sales. Higher~~sales due to higher transition costs ~~relating~~related to the relocation of manufacturing activities for certain products, the continued weakening of the U.S. dollar (which was favorable to reported sales ~~commissions on strong orders~~but unfavorable to reported operating margins) and the timing of new product ~~introductions and other initiatives during the first six months of fiscal year 2008~~introductions. These factors more than offset the positive impact of sales volume leverage.

Vacuum Technologies. The increase in Vacuum Technologies sales was driven by higher sales volume of ~~products. Higher~~a broad range of products and services, particularly those for industrial applications. The weaker U.S. dollar also had a positive impact on Vacuum Technologies sales ~~into industrial applications were partially offset by slightly lower sales into life science applications during the first six months of fiscal year 2008.~~growth.

Vacuum Technologies operating earnings for the first ~~six~~nine months of fiscal years 2008 and 2007 include the impact of share-based compensation expense of ~~$0.4~~$0.6 million and ~~$0.9~~$1.0 million, respectively. Excluding the impact of these items, the decrease in Vacuum Technologies operating earnings as a percentage of sales ~~reflects~~is primarily the ~~fact that~~result of the ~~segment had an unusually strong quarter in the first quarter of fiscal year 2007,~~weaker U.S. dollar, which ~~positively impacted operating profit margins for the first six months of fiscal year 2007. This decrease~~ was only partially offset by the positive impact of sales volume leverage in the first ~~six~~nine months of fiscal year 2008.

The following table presents comparisons of our sales and other selected consolidated financial results for the first ~~six~~nine months of fiscal years 2008 and 2007:


	Six Months Ended										Increase (Decrease)					Nine Months Ended
	March 28, 2008					March 30, 2007					Increase (Decrease)					June 27, 2008					June 29, 2007					Increase (Decrease)
	$			% of Sales		$			% of Sales		$			%		$			% of Sales		$			% of Sales		$			%
(dollars in millions, except per share data)
Sales	$	485.6		100.0	%	$	447.9		100.0	%	$	37.7		8.4	%	$	730.0		100.0	%	$	675.0		100.0	%	$	55.0		8.2	%

Gross profit		220.2		45.3			205.2		45.8			15.0		7.3			326.4		44.7			307.1		45.5			19.3		6.3


Operating expenses:
Selling, general and administrative		133.6		27.5			126.5		28.2			7.1		5.6			202.4		27.7			190.8		28.3	%		11.6		6.1
Research and development		35.4		7.3			31.7		7.1			3.7		11.5			53.9		7.4			48.6		7.2			5.3		10.9
Purchased in-process research and development																	1.5		0.2			—		—			1.5		100.0

Total operating expenses		169.0		34.8			158.2		35.3			10.8		6.8			257.8		35.3			239.4		35.5			18.4		7.7


Operating earnings		51.2		10.5			47.0		10.5			4.2		8.9			68.6		9.4			67.7		10.0			0.9		1.3
Impairment of private company equity investment		(3.0	)	(0.6	)		—		—			(3.0	)	100.0
Impairment of private company investments																	(3.0	)	(0.4	)		—		—			(3.0	)	(100.0	)
Interest income		3.7		0.8			2.6		0.6			1.1		39.9			4.9		0.7			4.2		0.6			0.7		14.8
Interest expense		(0.9	)	(0.2	)		(1.0	)	(0.2	)		0.1		(10.8	)		(1.3	)	(0.2	)		(1.4	)	(0.2	)		0.1		11.8
Income tax expense		(17.6	)	(3.6	)		(17.0	)	(3.8	)		(0.6	)	3.6			(24.5	)	(3.4	)		(24.3	)	(3.6	)		(0.2	)	(0.6	)

Net earnings	$	33.4		6.9	%	$	31.6		7.1	%	$	1.8		5.5	%	$	44.7		6.1	%	$	46.2		6.8	%	$	(1.5	)	(3.1	)%

Net earnings per diluted share	$	1.09				$	1.02				$	0.07				$	1.48				$	1.49				$	(0.01	)

Sales. As discussed under the headingSegment Results above, sales by the Scientific Instruments and Vacuum Technologies segments in the first ~~six~~nine months of fiscal year 2008 increased by ~~9.3%~~8.7% and ~~4.4%~~5.9%, respectively, compared to the first ~~six~~nine months of fiscal year 2007. ~~On a~~The growth in consolidated ~~basis,~~ sales ~~grew 8.4%~~was broad-based, with increases in ~~the first six months~~sales of ~~fiscal year 2008, with sales growth~~products for both industrial ~~(which includes environmental, food and energy)~~ and life science applications. ~~The~~Recent acquisitions and the weaker U.S. dollar also had a positive effect on the reported sales increases. Excluding sales from acquisitions completed since the third quarter of fiscal year 2007, consolidated sales in the first nine months of fiscal year 2008 increased by almost 8% compared to the first nine months of fiscal year 2007.

Sales by geographic region in the first ~~six~~nine months of fiscal years 2008 and 2007 were as follow:


	Six Months Ended												Nine Months Ended
	March 28, 2008				March 30, 2007				Increase (Decrease)				June 27, 2008				June 29, 2007				Increase (Decrease)
	$		% of Sales		$		% of Sales		$		%		$		% of Sales		$		% of Sales		$		%
(dollars in millions)
Sales by Geographic Region:
Geographic Region
North America	$	153.3	31.6	%	$	146.0	32.6	%	$	7.3	5.0	%	$	232.5	31.8	%	$	225.0	33.3	%	$	7.5	3.3	%
Europe		201.2	41.4			188.8	42.1			12.4	6.6			299.3	41.0			279.2	41.4			20.1	7.2
Asia Pacific		101.5	20.9			91.2	20.4			10.3	11.3			153.1	21.0			138.6	20.5			14.5	10.5
Latin America		29.6	6.1			21.9	4.9			7.7	34.8			45.1	6.2			32.2	4.8			12.9	40.3

Total company	$	485.6	100.0	%	$	447.9	100.0	%	$	37.7	8.4	%	$	730.0	100.0	%	$	675.0	100.0	%	$	55.0	8.2	%

The sales ~~increase~~increases in North America ~~was primarily~~and Latin America were driven by higher Scientific Instruments sales, ~~of analytical instruments, which was partially offset by slightly lower~~with Vacuum Technologies sales ~~of vacuum products. The increase~~essentially flat in sales in Europe was primarily attributable to increased demand for our analytical instruments, consumables and vacuum products, but was partially offset by lower sales of low-volume, high-selling price magnet-based products.those regions. The increases in sales in Europe and Asia Pacific ~~and Latin America~~ were ~~primarily~~ attributable to ~~stronger demand across a broad range of products, in particular analytical instruments~~higher sales by both the Scientific Instruments and ~~vacuum products.~~Vacuum Technologies segments.

~~As described above, the~~The sales increase in Europe was less pronounced compared to the first ~~six~~nine months of fiscal year 2007 due to the timing of sales of certain low-volume, high-selling price magnet-based products. We do not consider ~~these geographic shifts~~this to be indicative of any particular trend for magnet-based products as a whole, but rather to be reflective of the variability in results that these low-volume, high-selling price magnet-based products can create.

Gross Profit. Gross profit for the first ~~six~~nine months of fiscal year 2008 reflects the impact of ~~$2.9~~$4.9 million in amortization expense relating to acquisition-related intangible assets, ~~$0.6~~$1.2 million in amortization expense related to inventory written up ~~primarily~~to fair value in connection with ~~the IonSpec and Analogix Business~~recent acquisitions, ~~$0.7~~$1.2 million in restructuring and other related costs and share-based compensation expense of ~~$0.2~~$0.3 million. In comparison, gross profit for the first ~~six~~nine months of fiscal year 2007 reflects the impact of ~~$2.6~~$3.9 million in amortization expense relating to acquisition-related intangible assets, $0.5 million in amortization expense related to inventory written up to fair value in connection with the IonSpec acquisition, $0.7 million in restructuring and other related costs and share-based compensation expense of ~~$0.2~~$0.3 million. Excluding the impact of these items, the decrease in gross profit as a percentage of sales ~~decreased slightly,~~was primarily ~~as a~~the result of higher transition costs related to the relocation of manufacturing activities for certain products, the weaker U.S. dollar (which increased reported revenues but lowered reported gross profit margins). and, to a lesser extent, higher freight costs.

Selling, General and Administrative. Selling, general and administrative expenses for the first ~~six~~nine months of fiscal year 2008 included ~~$0.8~~$1.2 million in amortization expense relating to acquisition-related intangible assets, ~~$1.4~~$2.3 million in restructuring and other related costs and ~~$4.2~~$6.4 million in share-based compensation expense. In comparison, selling, general and administrative expenses for the first ~~six~~nine months of fiscal year 2007 included ~~$1.6~~$2.1 million in amortization expense relating to acquisition-related intangible assets, ~~$0.2~~$2.1 million in restructuring and other related costs and ~~$5.2~~$7.1 million in share-based compensation expense. Excluding the impact of these items, the slight decrease in selling, general and administrative expenses as a percentage of sales was primarily the

result of sales volume leverage and ~~cost reduction activities. The benefit from these positive factors was partially~~lower employee bonus accruals, largely offset by the continued weakening of the U.S. dollar, higher costs relating to sales commissions on strong orders, ~~and~~ the timing of new product introductions and ~~other initiatives~~the transition effect of acquisitions completed during the first ~~six~~nine months of fiscal year 2008.

Research and Development. Research and development expenses for the first ~~six~~nine months of fiscal year 2008 reflect the impact of ~~$0.5~~$0.8 million in restructuring and other related costs and share-based compensation expense of ~~$0.2~~$0.3 million. In comparison, research and development expenses for the first ~~six~~nine months of fiscal year 2007 reflect the impact of $0.3 million in restructuring and other related costs and share-based compensation expense of ~~$0.3~~$0.4 million. Excluding the impact of these items, research and development expenses were relatively flat as a percentage of sales.

Purchased In-Process Research and Development. In connection with the Oxford Diffraction acquisition in the third quarter of fiscal year 2008, we recorded a one-time charge of $1.5 million to immediately expense acquired in-process research and development related to projects that were in process but incomplete at the time of the acquisition.

Fiscal Year 2007 Plan. During the third quarter of fiscal year 2007, we committed to a plan to combine and optimize the development and assembly of most of our NMR and mass spectrometry products, to further centralize related administration and other functions and to reallocate certain resources toward more rapidly growing product lines and geographies.

The following table sets forth changes in our restructuring liability relating to the foregoing plan during the first ~~six~~nine months of fiscal year 2008:


	Employee- Related			Facilities- Related			Total			Employee- Related			Facilities- Related			Total
(in thousands)
Balance at September 28, 2007	$	2,222		$	—		$	2,222		$	2,222		$	—		$	2,222
Charges to expense, net		504			761			1,265			798			761			1,559
Cash payments		(1,201	)		(121	)		(1,322	)		(1,308	)		(185	)		(1,493	)
Foreign currency impacts and other adjustments		60			116			176			56			105			161

Balance at March 28, 2008	$	1,585		$	756		$	2,341
Balance at June 27, 2008										$	1,768		$	681		$	2,449

The restructuring charges of ~~$1.3~~$1.6 million recorded during the first ~~six~~nine months of fiscal year 2008 related to employee termination benefits and costs associated with the closure of leased facilities. We also incurred ~~$1.3~~$2.7 million in other restructuring-related costs which were comprised of ~~$1.0~~$1.7 million in employee retention costs and ~~$0.3~~$1.0 million in facilities-related costs including decommissioning costs and a non-cash charge for accelerated depreciation of assets to be disposed upon the closure of facilities.

Impairment of Private Company Equity Investment. During the first ~~six~~nine months of fiscal year 2008, we became aware of information which raised substantial doubt about the ability of a small, private company in which we hold a cost-method equity investment to continue as a going concern. Based on this information, we determined that the fair value of our investment had declined and that the decline was other-than-temporary. As a result, we wrote off the entire $3.0 million carrying value via an impairment charge in the ~~period.~~

~~Interest Income.~~~~The increase in interest income was primarily due to a higher average invested cash balance during the first six months~~second quarter of fiscal year 2008 compared to the first six months of fiscal year 2007. We currently believe that our interest income will likely be lower in the last six months of fiscal year 2008 due to the use of cash for acquisitions and stock repurchases during the first six months of fiscal year 2008 and because of lower interest rates on invested cash balances.2008.

Income Tax Expense.The effective income tax rate was ~~34.6%~~35.4% for the first ~~six~~nine months of fiscal year 2008, compared to ~~35.0%~~34.5% for the first ~~six~~nine months of fiscal year 2007. The ~~lower~~higher effective income tax rate in the first ~~six~~nine months of fiscal year 2008 was primarily due to higher U.S. taxes on foreign earnings, higher non-deductible compensation expense and a non-deductible in-process research and development charge related to the ~~release~~acquisition of ~~$1.5 million~~Oxford Diffraction in ~~tax reserves resulting from the positive~~

~~outcome of tax uncertainties,~~April 2008. These factors were partially offset by the benefit from a larger reduction in unrecognized tax benefits due to the lapse of certain ~~taxes on intercompany dividends, a write-down~~statutes of ~~non-U.S. deferred tax assets resulting from an income tax rate reduction and~~limitations in the ~~expiration~~first nine months of ~~the U.S. federal research and development tax credit in December 2007.~~fiscal year 2008.

Net Earnings. Net earnings for the first ~~six~~nine months of fiscal year 2008 reflect an in-process research and development charge of $1.5 million and the after-tax impacts of an impairment of a private company equity

investment of $3.0 million, ~~$3.7~~$6.1 million in acquisition-related intangible amortization, ~~$0.6~~$1.2 million in amortization related to inventory written up ~~primarily~~to fair value in connection with ~~the~~recent acquisitions, ~~of IonSpec and the Analogix Business, $2.6~~$4.2 million in restructuring and other related costs and ~~$4.7~~$7.0 million in share-based compensation expense. Net earnings for the first ~~six~~nine months of fiscal year 2007 reflect the after-tax impacts of ~~$4.2~~$6.0 million in acquisition-related intangible amortization, $0.5 million in amortization related to inventory written up to fair value in connection with the acquisition of IonSpec, ~~$0.2~~$3.1 million in restructuring and other related costs and ~~$5.7~~$7.8 million in share-based compensation expense. Excluding the after-tax impact of these items, the increase in net earnings ~~resulted~~in the first nine months of fiscal year 2008 was primarily ~~from~~attributable to higher sales volume (including sales volume leverage on operating expenses), partially offset by higher ~~interest income~~transition costs related to the relocation of manufacturing activities for certain products and ~~a lower effective income tax rate in the first six months of fiscal year 2008.~~higher costs relating to new product introductions.

We generated ~~$29.7~~$59.6 million of cash from operating activities in the first ~~six~~nine months of fiscal year 2008, compared to ~~$34.4~~$59.3 million generated in the first ~~six~~nine months of fiscal year 2007. ~~The decrease in cash~~Cash generated from operating activities ~~was primarily driven by~~remained essentially flat as a relative ~~increases~~increase in inventories ($~~16.7~~21.3 million) ~~and accounts receivable ($3.1 million) and~~was offset by a relative decrease in ~~deferred profit~~accounts receivable ($~~4.0~~8.5 million)~~, partially offset by~~ and relative increases in accrued liabilities ($~~11.8~~2.9 million) and accounts payable ($~~7.1~~7.7 million) ~~as well as higher net earnings excluding the impact of an impairment of a private company equity investment.~~. The relative increase in inventories was primarily due to a build-up of inventory to support increased orders, new product introductions and the transition of certain products to new manufacturing locations. The relative ~~increase~~decrease in accounts receivable was primarily due to ~~higher sales. The relative decrease~~stronger collection efforts in ~~deferred profit was due to the timing of revenue recognition on certain large magnet-based systems during~~ the first ~~six~~nine months of fiscal year 2008. The relative increase in accrued liabilities was primarily due to an increase in contract advances from customers during the first ~~six~~nine months of fiscal year 2008. The relative increase in accounts payable was primarily due to higher purchasing ~~activity to support higher sales and the timing~~ of ~~vendor payments.~~inventories.

We used ~~$23.6~~$68.3 million of cash for investing activities in the first ~~six~~nine months of fiscal year 2008, which compares to ~~$7.6~~$12.8 million used for investing activities in the first ~~six~~nine months of fiscal year 2007. The increase in cash used for investing activities in the first ~~six~~nine months of fiscal year 2008 was primarily the result of the ~~acquisition~~acquisitions of the Analogix Business in November 2007 and Oxford Diffraction in April 2008 as well as higher net capital expenditures due primarily to the construction of our IRD center in Walnut Creek, California.

We used ~~$55.7~~$69.8 million of cash for financing activities in the first ~~six~~nine months of fiscal year 2008, which compares to ~~$27.6~~$38.6 million used for financing activities in the first ~~six~~nine months of fiscal year 2007. The increase in cash used for financing activities in the first nine months of fiscal year 2008 was primarily due to higher expenditures to repurchase and retire common stock (such expenditures were made in both periods as a result of a continued effort to utilize excess cash to reduce the number of outstanding common shares)~~. The increase in cash used for financing activities was partially offset by~~, lower proceeds from the issuance of common stock ~~due~~(due to lower stock option exercise ~~volume during the first six months~~volume) and higher repayments of ~~fiscal year 2008 compared to the first six months of fiscal year 2007.~~debt.

We maintain relationships with banks in many countries from whom we sometimes obtain bank guarantees and short-term standby letters of credit. These guarantees and letters of credit relate primarily to advance payments and deposits made to our subsidiaries by customers for which separate liabilities are recorded in the unaudited condensed consolidated financial statements. As of ~~March 28,~~June 27, 2008, a total of ~~$21.6~~$23.2 million of these bank guarantees and letters of credit were outstanding. No amounts had been drawn by beneficiaries under these or any other outstanding guarantees or letters of credit as of that date.

As of ~~both March 28,~~June 27, 2008, ~~and September 28, 2007,~~ we had ~~a $25.0~~an $18.8 million term loan outstanding with a U.S. financial ~~institution~~institution. The balance outstanding under this term loan was $25.0 million at aSeptember 28, 2007. As of both June 27, 2008 and September 28, 2007, the fixed interest rate ofon the term loan was 6.7%. The term loan contains certain covenants that limit future borrowings and the payment of cash dividends and require the maintenance of certain levels of working capital and operating results. We were in compliance with all restrictive covenants of the term loan agreement at ~~March 28,~~June 27, 2008.

In connection with certain acquisitions, we have accrued a portion of the purchase price that has been retained to secure the respective sellers’ indemnification obligations.

The following table summarizes outstanding purchase price amounts retained and the date they will become payable (net of any indemnification claims) as of ~~March 28,~~June 27, 2008:

In addition to the above ~~amount,~~amounts, the final $0.7 million retained in connection with the acquisition of IonSpec ~~Corporation (“IonSpec”)~~ in February 2006 was paid during the first ~~six~~nine months of fiscal year 2008.

As of ~~March 28,~~June 27, 2008, ~~up to a maximum of $33.3 million could be payable through December 2010 under~~we had several outstanding contingent consideration arrangements relating to acquired businesses. Amounts subject to these arrangements can be earned over the respective measurement period, depending on the performance of the acquired business relative to certain financial and/or operational targets.

The following table summarizes ~~key terms of outstanding~~ contingent consideration arrangements as of ~~March 28,~~June 27, 2008:

In addition to the above amounts, up to $10.0 million in contingent consideration could be payable over a three-year period relating to Oxford Diffraction, which was acquired in April 2008 for approximately $37 million in cash and assumed net debt.

During the first ~~six~~nine months of fiscal year 2008, we paid $4.0 million for the final contingent consideration payment related to ~~the acquisition of~~ Magnex Scientific Limited, which we acquired in November 2004.

The Distribution Agreement provides that we are responsible for certain litigation to which VAI was a party, and further provides that we will indemnify VMS and VSEA for one-third of the costs, expenses and other liabilities relating to certain discontinued, former and corporate operations of VAI, including certain environmental liabilities (see Note 12 of the Notes to the Unaudited Condensed Consolidated Financial Statements).

As of ~~March 28,~~June 27, 2008, we had cancelable commitments to a contractor for capital expenditures totaling approximately ~~$22.4~~$21.3 million relating to the construction of our ~~information rich detection~~IRD center in Walnut Creek, California. In the event that these commitments are canceled for reasons other than the contractor’s default, we may be responsible for reimbursement of actual costs incurred by the contractor. We had no material non-cancelable commitments for capital expenditures as of ~~March 28,~~June 27, 2008. In the aggregate, we currently anticipate that our capital expenditures will be ~~about 3.5%~~approximately 2.5% of sales for the full fiscal year 2008.

As discussed above under the headingRestructuring Activities, in April 2007, we committed to a plan to combine and optimize the development and assembly of most of our NMR and mass spectrometry products, to further centralize related administration and other functions and to reallocate certain resources toward more rapidly growing product lines and geographies. In connection with this plan, we expect to make capital expenditures of up to $25 million, which began in the fourth quarter of fiscal year 2007 and will continue through ~~the first half of~~

fiscal year 2009. We expect that a significant portion of these expenditures will fall within our typical capital spending pattern (of approximately 3% of sales) measured over a two-year period. We also expect to incur total restructuring and other related costs associated with this plan of between ~~$10.0~~$12.0 million and $14.0 million, of which $4.3 million was incurred in fiscal year 2007 and ~~$2.3~~$4.2 million was incurred in the first ~~six~~nine months of fiscal year 2008. Some portion of these costs is expected to be settled through the fourth quarter of fiscal year 2009, except for certain lease termination-related costs, which might be settled as late as the fourth quarter of fiscal year 2012. A total of ~~$8.5~~$10.5 million to $12.5 million of these costs are expected to result in cash expenditures.

In February 2008, our Board of Directors approved a new stock repurchase program under which we ~~were~~are authorized to utilize up to $100 million to repurchase shares of our common stock. This repurchase program is effective through December 31, 2009. During the ~~fiscal quarter~~nine months ended ~~March 28,~~June 27, 2008, we repurchased and retired ~~376,000~~567,000 shares under this authorization at an aggregate cost of ~~$20.2~~$30.5 million. As of ~~March 28,~~June 27, 2008, we had remaining authorization to repurchase ~~$79.8~~$69.5 million of our common stock under this repurchase program.

In January 2007, our Board of Directors approved a stock repurchase program under which we were authorized to utilize up to $100 million to repurchase shares of our common stock. This repurchase program was effective until December 31, 2008. During the first ~~six~~nine months of fiscal year 2008, we repurchased and retired 876,000 shares under this repurchase program at an aggregate cost of $50.4 million, which completed this repurchase program.

Our liquidity is affected by many other factors, some based on the normal ongoing operations of the business and others related to the uncertainties of the industries in which we compete and global economies. Although our cash requirements will fluctuate based on the timing and extent of these factors, we believe that cash generated from operations, together with our current cash balance and borrowing capability, will be sufficient to satisfy commitments for capital expenditures and other cash requirements for the next 12 months.

The following table summarizes the amount and estimated timing of future cash expenditures relating to principal payments on outstanding long-term debt, minimum rentals due for certain facilities and other leased assets under long-term, non-cancelable operating leases and other long-term liabilities as of ~~March 28,~~June 27, 2008:


	Six Months Ending Oct. 3, 2008			Fiscal Years																	Total		Fiscal Quarter Ending Oct. 3, 2008			Fiscal Years
			2009			2010			2011			2012			2013			Thereafter			Total		Fiscal Quarter Ending Oct. 3, 2008		2009			2010			2011			2012			2013			Thereafter			Total
(in thousands)	Six Months Ending Oct. 3, 2008
Operating leases	$	5,295		$	7,569		$	5,231		$	2,790		$	2,230		$	1,810		$	3,836	$	28,761	$	3,001		$	9,472		$	6,683		$	3,356		$	2,252		$	1,780		$	3,762		$	30,306
Long-term debt (including current portion)		6,250			—			6,250			—			6,250			—			6,250		25,000		—			—			6,250			—			6,250			—			6,250			18,750
Other long-term liabilities		502			4,443			3,356			3,284			2,805			2,684			25,761		42,835		502			4,455			3,898			3,511			2,934			2,742			26,164			44,206

Total	$	12,047		$	12,012		$	14,837		$	6,074		$	11,285		$	4,494		$	35,847	$	96,596	$	3,503		$	13,927		$	16,831		$	6,867		$	11,436		$	4,522		$	36,176		$	93,262

As of ~~March 28,~~June 27, 2008, we did not have any off-balance sheet commercial commitments that could result in a significant cash outflow upon the occurrence of some contingent event, except for contingent payments of up to a maximum of ~~$33.3~~$43.9 million related to acquisitions as discussed underLiquidity and Capital Resources above, the specific amounts of which are not currently determinable.

In September 2006, the FASB issued SFAS 157, Fair Value Measurements. SFAS 157 defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles and expands disclosures about fair value measurements. SFAS 157 applies to previous accounting pronouncements that require or permit fair value measurements. SFAS 157 is effective for fiscal years beginning after November 15, 2007, with certain exceptions which are described below. In February 2008, the FASB issued FASB Staff Position (“FSP”) 157-1, Application of FASB Statement No. 157 to FASB Statement No. 13 and Other Accounting Pronouncements That Address Fair Value Measurements for Purposes of Lease Classification or Measurement under Statement 13, which amends SFAS 157 to exclude certain leasing transactions from its scope. Also in February 2008, the FASB issued FSP 157-2,Effective Date of FASB Statement No. 157,which delays the effective date of SFAS 157 for all nonfinancial assets and nonfinancial liabilities to fiscal years beginning after November 15, 2008, except for items that are recognized or disclosed at fair value in the financial statements on a recurring basis (at least annually). We do not expect the adoption of SFAS 157 to have a material impact on our financial condition or results of operations.

In February 2007, the FASB issued SFAS 159,The Fair Value Option for Financial Assets and Financial Liabilities—Including an amendment of FASB Statement 115, which provides companies with an option to measure eligible financial assets and liabilities in their entirety at fair value. The fair value option may be applied instrument by instrument, and may be applied only to entire instruments. If a company elects the fair value option for an eligible item, changes in the item’s fair value must be reported as unrealized gains and losses in earnings at each subsequent reporting date. SFAS 159 is effective for fiscal years beginning after November 15, 2007. We are evaluating the options provided under SFAS 159 and their potential impact on our financial condition and results of operations if implemented.

In December 2007, the FASB issued SFAS 141(revised 2007),Business Combinations, (“SFAS 141(R)”). SFAS 141(R) retains the fundamental requirements of the original pronouncement requiring that the purchase method be used for all business combinations but also provides revised guidance for recognizing and measuring identifiable assets and goodwill acquired, liabilities assumed, and any noncontrolling interest in the acquiree. It also requires the recognition of assets acquired and liabilities assumed arising from contingencies, the capitalization of in-process research and development at fair value, and the expensing of acquisition-related costs as incurred.SFAS 141(R) is effective for fiscal years beginning after December 15, 2008. We are currently evaluating the requirements of SFAS 141(R) and do not expect its adoption in the first quarter of fiscal year 2010 to have a material impact on our financial condition or results of operations. However, in the event that we complete acquisitions subsequent to our adoption of SFAS 141(R), the application of its provisions will likely have a material impact on our results of operations, although we are not currently able to estimate that impact.

In December 2007, the FASB issued SFAS 160,Noncontrolling Interests in Consolidated Financial Statements—an amendment of ARB No. 51. SFAS 160 requires that ownership interests in subsidiaries held by parties other than the parent and the amount of consolidated net income be clearly identified, labeled and presented in the consolidated financial statements. It also requires once a subsidiary is deconsolidated, any retained noncontrolling equity investment in the former subsidiary be initially measured at fair value. Sufficient disclosures are required to clearly identify and distinguish between the interests of the parent and the interests of the noncontrolling owners. SFAS 160 is effective for fiscal years beginning after December 15, 2008, and requires retroactive adoption of the presentation and disclosure requirements for existing minority interests. All other requirements are applied prospectively. We do not expect the adoption of SFAS 160 to have a material impact on our financial condition or results of operations.

related hedged items on our financial condition and results of operations. SFAS 161 is effective for fiscal years beginning after November 15, 2008. We do not expect the adoption of SFAS 161 to have a material impact on our financial condition or results of operations.

In April 2008, the FASB issued FSP 142-3,Determination of the Useful Life of Intangible Assets, which amends the factors that should be considered in developing renewal or extension assumptions used to determine the useful life of a recognized intangible asset. The intent of FSP 142-3 is to improve the consistency between the useful life of a recognized intangible asset under SFAS 142,Goodwill and Other Intangible Assets, and the period of expected cash flows used to measure the fair value of the asset under SFAS 141(R),Business Combinations, and other accounting literature. FSP 142-3 is effective for fiscal years beginning after December 15, 2008 and must be applied prospectively to intangible assets acquired after the effective date. Early adoption is prohibited. Given that FSP 142-3 applies to intangible assets acquired after the effective date, we are not yet able to determine whether its adoption will have a material impact on our financial condition or results of operations.

Foreign Currency Exchange Risk. We enter into foreign exchange forward contracts to minimize the short-term impact of foreign currency fluctuations on assets and liabilities denominated in non-functional currencies. From time to time, we also enter into foreign exchange forward contracts to minimize the impact of foreign currency fluctuations on forecasted transactions. The success of our hedging activities depends on our ability to forecast balance sheet exposures and transaction activity in various foreign currencies. To the extent that these forecasts are overstated or understated during periods of currency volatility, we could experience unanticipated currency gains or losses. However, we believe that in most cases any such gains or losses would be substantially offset by losses or gains from the related foreign exchange forward contracts. We therefore believe that the direct effect of an immediate 10% change in the exchange rate between the U.S. dollar and all other currencies is not reasonably likely to have a material adverse effect on our financial condition or results of operations.

At ~~March 28,~~June 27, 2008, there were no outstanding forward contracts designated as cash flow hedges of forecasted transactions. During the first ~~six~~nine months of fiscal year 2008, no foreign exchange gains or losses from cash flow hedge ineffectiveness were recognized.

Our foreign exchange forward contracts generally range from one to 12 months in original maturity. A summary of all foreign exchange forward contracts that were outstanding as of ~~March 28,~~June 27, 2008 follows:


	Notional Value Sold		Notional Value Purchased		Notional Value Sold		Notional Value Purchased
(in thousands)
Australian dollar					$	—	$	43,281
Euro	$	—	$	30,788		—		28,715
Australian dollar		—		44,803
British pound		—		9,716		—		11,971
Swiss franc						—		4,510
Canadian dollar						3,255		—
Japanese yen		5,586		—		3,248		—
Canadian dollar		3,569		—
Swedish krona						2,337		—
Polish zloty						—		1,634

Total	$	9,155	$	85,307	$	8,840	$	90,111

Interest Rate Risk. We have no material exposure to market risk for changes in interest rates. We invest any excess cash primarily in short-term U.S. Treasury securities and money market funds, and changes in interest rates would not be material to our financial condition or results of operations. We enter into debt obligations principally to support general corporate purposes, including working capital requirements, capital expenditures and acquisitions. At ~~March 28,~~June 27, 2008, our debt obligations had fixed interest rates.

Based upon rates currently available to us for debt with similar terms and remaining maturities, the carrying amounts of long-term debt approximate their estimated fair values.

Although payments under certain of our operating leases for our facilities are tied to market indices, we are not exposed to material interest rate risk associated with our operating leases.

Principal Amounts and Related Weighted-Average Interest Rates By Year of Maturity


	Six Months Ending Oct. 3, 2008			Fiscal Years																		Total			Fiscal Quarter Ending Oct. 3, 2008			Fiscal Years																		Total
	Six Months Ending Oct. 3, 2008			2009			2010			2011			2012			2013			Thereafter			Total			Fiscal Quarter Ending Oct. 3, 2008			2009			2010			2011			2012			2013			Thereafter			Total
(dollars in thousands)
(in thousands)
Long-term debt (including current portion)	$	6,250		$	—		$	6,250		$	—		$	6,250		$	—		$	6,250		$	25,000		$	—		$	—		$	6,250		$	—		$	6,250		$	—		$	6,250		$	18,750
Average interest rate		6.7	%		—	%		6.7	%		—	%		6.7	%		—	%		6.7	%		6.7	%		—	%		—	%		6.7	%		—	%		6.7	%		—	%		6.7	%		6.7	%

Defined Benefit Retirement Plans. Most of our retirement plans, including all U.S.-based plans, are defined contribution plans. However, we also provide defined benefit pension plans in certain countries outside of the U.S. Our obligations under these defined benefit plans will ultimately be settled in the future and are therefore subject to estimation. Defined benefit pension accounting under SFAS 87,Employers’ Accounting for Pensions, is intended to reflect the recognition of future benefit costs over the employees’ estimated service periods based on the terms of the pension plans and the investment and funding decisions made by us.

For our defined benefit pension plans, we make assumptions regarding several variables including the expected long-term rate of return on plan assets and the discount rate in order to determine defined benefit pension plan expense for the year. This expense is referred to as “net periodic pension cost.” We assess the expected long-term rate of return on plan assets and discount rate assumption for each defined benefit plan based on relevant market conditions as prescribed by SFAS 87 and make adjustments to the assumptions as appropriate. On an annual basis, we analyze the rates of return on plan assets and discount rates used and determine that these rates are reasonable. For rates of return, this analysis is based on a review of the nature of the underlying assets, the allocation of those assets and their historical performance relative to the overall markets in the countries where the related plans are effective. Historically, our assumed asset allocations have not varied significantly from the actual allocations. Discount rates are based on the prevailing market long-term interest rates in the countries where the related plans are effective. As of September 28, 2007, the estimated long-term rate of return on our defined benefit pension plan assets ranged from 0.5% to 7.1% (weighted-average of 5.9%), and the assumed discount rate for our defined benefit pension plan obligations ranged from 2.0% to 5.7% (weighted-average of 5.5%).

If any of these assumptions were to change, our net periodic pension cost would also change. We incurred net periodic pension cost relating to our defined benefit pension plans of $2.3 million in fiscal year 2007, $2.3 million in fiscal year 2006 and $1.6 million in fiscal year 2005 (excluding a settlement loss), and expect our net periodic pension cost to be approximately $1.7 million in fiscal year 2008. A one percent decrease in the weighted-average estimated return on plan assets or assumed discount rate would increase our net periodic pension cost for fiscal year 2008 by $1.1 million or $0.4 million, respectively. As of September 28, 2007, our projected benefit obligation relating to defined benefit pension plans was $53.3 million. A one percent decrease in the weighted-average estimated discount rate would increase this obligation by $11.0 million.

Disclosure Controls and Procedures. Based on the evaluation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) required by Rules 13a-15(b) and 15d-15(b) of the Exchange Act, our Chief Executive Officer and the Chief Financial Officer have concluded that as of the end of the period covered by this Quarterly Report on Form 10-Q ~~(March 28,~~(June 27, 2008), our disclosure controls and procedures were effective.

Inherent Limitations on the Effectiveness of Controls. The Company’s management, including the Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls or our internal control over financial reporting will prevent all error and all fraud. A control system, no matter how well designed and operated, can only provide reasonable, not absolute, assurance that the control system’s objectives will be met. Further, the design of a control system must reflect the fact that the benefits of controls must be considered relative to their costs. Due to the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons or by collusion of two or more people. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

Changes in Internal Control over Financial Reporting. There was no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that occurred during the ~~second~~third quarter of our fiscal year 2008 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

See Item 1A—Risk Factors presented in our Annual Report on Form 10-K for the fiscal year ended September 28, 2007, which we encourage you to carefully consider.

(c) February 2008 Stock Repurchase Program.The following table summarizes information relating to our stock repurchases during the ~~second~~third quarter of fiscal year 2008:

~~January 2007 Stock Repurchase Program.~~~~The following table summarizes information relating to our stock repurchases during the second quarter of fiscal year 2008:~~

At our Annual Meeting of Stockholders held on January 31, 2008, our stockholders considered and voted on three matters: (1) the election of two Class III directors to the Board of Directors for three-year terms; (2) the ratification of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for fiscal year 2008; and (3) the approval of our amended and restated Omnibus Stock Plan. Our stockholders’ voting on these matters was as follows:

Pursuant to the rules of The Nasdaq Stock Market, Inc., Proposals One and Two allowed certain brokers to vote without receipt of instructions from clients, so there were no broker non-votes. There were 2,125,891 broker non-votes on Proposal Three.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


Delaware		77-0501995
(State or Other Jurisdiction of Incorporation or Organization)		(IRS Employer Identification No.)

3120 Hansen Way, Palo Alto, California		94304-1030
(Address of Principal Executive Offices)		(Zip Code)


Large accelerated filer x		Accelerated filer ¨
Non-accelerated filer ¨ (Do not check if a smaller reporting company)		~~Non-accelerated filer~~Smaller reporting company ¨


		Page

PART I	Financial Information

Item 1.	Financial Statements:

	Unaudited Condensed Consolidated Statement of Earnings	3

	Unaudited Condensed Consolidated Balance Sheet	4

	Unaudited Condensed Consolidated Statement of Cash Flows	5

	Notes to the Unaudited Condensed Consolidated Financial Statements	6

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	2324

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	3638

Item 4.	Controls and Procedures	3740

PART II	Other Information

Item 1A.	Risk Factors	3941

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	39

~~Item 4.~~	~~Submission of Matters to a Vote of Security Holders~~	4041

Item 6.	Exhibits	4041


Acquired ~~business~~Business	Remaining Amount Available (maximum)	Measurement ~~period~~Period	Measurement ~~period end date~~Period End Date
	(in millions)
~~Analogix~~PL International Ltd.	$15.3	3 years	December 2008
IonSpec Corporation	14.0	3 years	April 2009
Oxford Diffraction	10.0	3 years	April 2011
Analogix Business	4.0 ~~million~~	3 years	December 2010
~~IonSpec~~Other	0.6	2 years	July 2010

Total	$~~14.0 million~~43.9	~~3 years~~	~~April 2009~~
~~Polymer Labs~~	~~$15.3 million~~	~~3 years~~	~~December 2008~~


	March 28, 2008
	Gross		Accumulated Amortization			Net
(in thousands)
Intangible assets
Existing technology	$	16,786	$	(9,259	)	$	7,527
Patents and core technology		34,224		(12,763	)		21,461
Trade names and trademarks		2,457		(1,800	)		657
Customer lists		12,238		(10,081	)		2,157
Other		3,174		(2,531	)		643

Total	$	68,879	$	(36,434	)	$	32,445


	Pretax Earnings						Pretax Earnings
	Fiscal Quarter Ended						Nine Months Ended
	June 27, 2008			June 29, 2007			June 27, 2008			June 29, 2007
(in millions)
Scientific Instruments	$	12.2		$	17.4		$	54.5		$	58.0
Vacuum Technologies		7.8			7.8			24.3			23.9

Total industry segments		20.0			25.2			78.8			81.9
General corporate		(2.6	)		(4.5	)		(10.2	)		(14.2	)
Impairment of private company equity investment		—			—			(3.0	)		—
Interest income		1.2			1.6			4.9			4.2
Interest expense		(0.4	)		(0.5	)		(1.3	)		(1.4	)

Total pretax earnings	$	18.2		$	21.8		$	69.2		$	70.5


Acquired Business	Retained Amount	Date Payable
	(in millions)
Analogix Business	$1.3 ~~million~~	November 2009
Other	0.3	April 2009

Total	$1.6


Acquired Business	Remaining Amount Available (maximum)	Measurement Period	Measurement Period End Date
	(in millions)
PL International Ltd.	$15.3	3 years	December 2008
IonSpec Corporation	14.0	3 years	April 2009
Oxford Diffraction	10.0	3 years	April 2011
Analogix Business	4.0	3 years	December 2010
~~$4.0 million~~Other	0.6	2 years	July 2010

~~3 years~~Total	~~December 2010~~
~~IonSpec~~ $43.9	~~$14.0 million~~	~~3 years~~
	~~April 2009~~
~~Polymer Labs~~	~~$15.3 million~~	~~3 years~~	~~December 2008~~


Fiscal Month	Shares Repurchased	Average Price Per Share		Total Value of Shares Repurchased as Part of Publicly Announced Plan (1)(2)		Maximum Total Value of Shares that May Yet Be Purchased Under the Plan
(In thousands, except per share amounts)
Balance – December 28, 2007						$	—
December 29, 2007 – January 25, 2008	—	$	—	$	—		—
January 26, 2008 – February 22, 2008	343		54.00		18,517		81,483
February 23, 2007 – March 28, 2008	33		52.60		1,731	$	79,752

Total shares repurchased	376	$	53.88	$	20,248


Fiscal Month	Shares Repurchased ⁽¹⁾	Average Price Per Share⁽¹⁾		Total Value of Shares Repurchased as Part of Publicly Announced Plan⁽²⁾⁽³⁾		Maximum Total Value of Shares that May Yet Be Purchased Under the Plan
(in thousands, except per share amount)
Balance – March 28, 2008						$	79,752
March 29, 2008 – April 25, 2008	—	$	—	$	—	$	79,752
April 26, 2008 – May 23, 2008	152		53.25		7,987	$	71,765
May 24, 2008 – June 27, 2008	42		54.46		2,260	$	69,505

Total shares repurchased	194	$	53.51	$	10,247


	Votes For	Votes Against	Votes Withheld	Abstentions
Proposal One—Election of Directors:
Nominee: Garry W. Rogerson	27,985,860	—	835,986	—
Nominee: Elizabeth E. Tallett	24,904,570	—	3,907,276	—

Proposal Two—Ratification of Appointment of PricewaterhouseCoopers LLP	28,372,670	332,924	—	106,252

Proposal Three—Approval of Amended and Restated Omnibus Stock Plan	22,531,080	3,894,694	—	260,181


Exhibit No.	Exhibit Description	Incorporated by Reference			~~Filed~~ ~~Herewith~~
Exhibit No.	Exhibit Description	Form	Date	Exhibit Number

10.29*	~~Form of Nonqualified Stock Option Agreement between Varian, Inc. and Non-Employee Directors—For New Director/Chairman Grants (used beginning February 1, 2008)~~				X

10.30*	~~Form of Nonqualified Stock Option Agreement between Varian, Inc. and Non-Employee Directors—For Annual Director Grants (used beginning February 1, 2008)~~				XFiled Herewith

31.1	Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.				X

31.2	Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.				X

32.1	Certification of Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2	Certification of Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.


	VARIAN, INC. (Registrant)

Date: ~~May 6,~~August 5, 2008	By:	/s/ G. EDWARD MCCLAMMY
		G. Edward McClammy Senior Vice President, Chief Financial Officer and Treasurer (Duly Authorized Officer and Principal Financial Officer)